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Background 
Autonomic imbalance and depression of baroreceptor function relate to prognosis 
and risk of sudden death in heart failure. The analysis of heart rate variability can 
give insight into these autonomic abnormalities. 
The low/high frequency ratio derived from power spectral analysis of heart rate 
variability has been proposed as a noninvasive method to assess sympatho-vagal 
balance. However the effects of different respiratory rates or posture are rarely 
accounted for, but may be relevant in heart failure patients in whom clinical 
improvement is accompanied by a fall in respiratory rate and increased proportion of 
the day in the upright position. 
In addition there is little information on the effect of treatments particularly the 
different P-adrenoreceptor antagonists on heart rate variability in patients with heart 
failure. 
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Methods and Results 
Heart rate variability was measured in patients with stable chronic heart failure 
(CHF) and normal controls by the standard Time-Domain methods and spectral 
analysis. Arterial baroreflex sensitivity was assessed using the "a-angle" coherence 
method in which the gain of the reflex is obtained by relating the fluctuations in the 
RR interval to those in the systolic blood pressure at the same frequency. Both 24 
hour ambulatory ECG and short 5 minute simultaneous recordings of the ECG and 
blood pressure under controlled conditions were used for analysis. 
The main results were: 
1. During controlled breathing in the supine position the power of the high 
frequency component was significantly greater at 10 breaths/min. compared 
to 20 breaths/min. in heart failure patients. On standing, controlled breathing 
in heart failure patients produced less change in high frequency power 
(p=0.054) but low/high frequency ratio at lower respiratory rates was reduced 
(p=0.05). In normals, as expected, respiratory rate had a highly significant 
effect on HF power. Also, in normals there was the expected increase in 
heart rate low frequency power (p=0.04) moving from supine to standing 
with an increase in low/high frequency ratio, while in CHF patients this was 
absent reflecting blunted cardiovascular reflexes. 
2. Slow breathing induced highly significant increases in baroreflex sensitivity, 
both in controls and in CHF patients, which correlated with the value 
obtained during spontaneous breathing. In addition, systolic and diastolic 
blood pressure decreased in CHF patients. 
3. After 12 weeks treatment with the p-blocker metoprolol baroreceptor gain 
improved significantly measured both supine (p=0.03) and standing 
(p=0.009) and this was associated with a significant increase in RR HF power 
(p = 0.008). There were no significant changes after treatment with the 
vasodilating p-blocker celiprolol or placebo. 
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4. In a second study comparing metoprolol with carvedilol it was found that 
metoprolol was also superior to carvedilol in improving baroreceptor gain 
although heart rate reductions were similar in both groups. 
Conclusions 
These data suggest that respiratory rate and changes in posture have a significant 
effect on measurements derived from spectral analysis of heart rate and blood 
pressure variability. Studies that use power spectral analysis as a measure of 
sympatho-vagal balance should control for these variables. 
In patients with CHF, slow breathing, in addition to improving oxygen saturation and 
exercise tolerance as has been previously shown, may be beneficial by increasing 
baroreflex sensitivity. 
Metoprolol restored baroreceptor gain towards normal and increased vagal tone in 
CHF, but the vasodilator P- blocker celiprolol did not. 
Metoprolol also appeared to be superior to the non-selective P-blocker carvedilol and 
this may be due to a direct central effect of metoprolol which is greater than that of 
carvedilol despite both being lipophilic drugs. 
Thus this study has confirmed that heart rate variability and baroreceptor function are 
both depressed in CHF patient and that slow breathing can improve baroreceptor 
function but metoprolol therapy improves both. In addition, this study demonstrates 
the advantages of spectral analysis in the frequency domain of short recordings under 


























































a angle alpha angle 
P-blockade beta-blockade 
P-blocker beta-blocker 
ACEI angiotensin converting enzyme inhibitors 
AURA angiotensin II receptor antagonist 
ANP atrial natriuretic peptides 
ANS autonomic nervous system 
AP arterial pressure 
ARP abnormal relaxation pattern 
BNP brain (ventricular) natriuretic peptide 
BP blood pressure 
C celiprolol 
CLV cycle length variability 
CHF chronic heart failure 
DBP diastolic blood pressure 
DT deceleration time of E wave 
E/A ratio of peak early E wave velocity over peak A wave velocity 
ECG electrocardiograph 
ETT exercise tolerance test 
FFT Fast Fourier Transform 
FS fractional shortening 
HD heart disease 
HF power high frequency power (0.15 - 0.40 Hz) 
HF high frequency 
Holter 24-hour ambulatory electrocardiogram 
HR heart rate 
HRV heart rate variability 
HTHD hypertensive heart 
Hz Hertz 
ICM ischemic cardiomyopathy 
IDC idiopathic dilated cardiomyopathy 
IVRT isovolumic relaxation time 
LF power low frequency power (0.04-0.15 Hz) 
LF low frequency 
LV left ventricular 
LVEDD left ventricular end diastolic dimension 
LVEF left ventricular ejection fraction 
M metoprolol 
MI myocardial infarction 
MUGA radionuclide ventriculography 
NN mean of all coupling intervals between normal beats 
NSVT non-sustained ventricular tachycardia 
NYHA New York Heart Association 
P placebo 
pNN50 proportion of adjacent RRs more than 50 msec different 
Resp respiration 
viii 
RFP restrictive filling pattern 
rMSSD root-mean square of difference of successive RRs 
SBP systolic blood pressure 
SD mean of all 5 minute standard deviation of RRs 
SDANN standard deviation of 5 minute mean RR intervals 
SDNN standard deviation about the mean 
SEM standard error of mean 
Spont Resp spontaneous respiration 
Total power all frequencies (0.01 - 1.0 Hz) 
vs versus 
VLF very low frequency 
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1 INTRODUCTION 
1.1 Definition of Heart Rate Variability 
The term heart rate variability (HRV) is used to describe the variation of heart 
rate or the periodic change of heart rhythm over time. It is the recurrent changes in 
R-R intervals on an electrocardiogram (ECG) characteristic of a balanced cardiac 
control mechanism. In the absence of physical activity, postural changes and 
emotional stimuli, HRV represents the continuous, autonomically mediated 
alterations of the sinus node discharge rate. 
Research suggests that decreased variability in normal-to-normal beat 
intervals can be a prognostic indicator for certain disease states. The influence of the 
autonomic nervous system has considerable effect on the integrity of cardiovascular 
homeostasis. It is the antagonistic components of the autonomic system that 
comprise the core of study of heart rate variability. 
There are several approaches in the evaluation of HRV. The most frequently 
used technologies can be grouped into either the time domain or the frequency 
domain analysis (Ghuran and Malik 2001) 
1.2 Physiology 
1.2.1 Review of Autonomic Nervous System and Influence of Heart Rate 
The autonomic nervous system (ANS) controls the visceral functions of the 
body including arterial pressure, gastrointestinal motility and secretion, urinary 
output, body temperature, and cardiac muscle. Control is activated primarily by 
centers located in the spinal cord, brain stem, and hypothalamus. The heart is richly 
innervated with nerves from the autonomic nervous system (Figure 1, page 2). Each 
autonomic pathway consists of preganglionic neuron with its cell body within the 
central nervous system (CNS) and a postganglionic neuron with its cell body in an 
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autonomic ganglion outside the CNS. The autonomic signals in turn are transmitted 
to the body through two major subdivisions: the sympathetic and parasympathetic 
divisions. 
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Figure 1 Innervation of Heart: Schema 
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Sympathetic system 
Widespread activation of sympathetic system prepares the body for intense 
physical activity in an emergency. As a result, the heart rate increases, blood glucose 
rises, and blood is diverted to the skeletal muscles, away from the viscera and skin. 
Parasympathetic system 
The effects of parasympathetic nerve stimulation in many ways oppose the 
effects of sympathetic response. However, it is not normally activated as a whole. 
Selective stimulation of separate parasympathetic nerves can result in slowing of the 
heart, vasodilatation in visceral blood vessels, and increased activity of the digestive 
tract. The parasympathetic nervous system regulates activities that conserve and 
restore body energy. 
The heart, like most organs is well supplied with both sympathetic and 
parasympathetic (vagal) nerves which affect cardiac pumping in two ways: by 
changing the heart rate and by altering the strength of the heart's contractions. The 
sympathetic nerves typically cause excitation whilst parasympathetic nerves cause 
inhibition. 
The different responses of visceral organs to sympathetic and 
parasympathetic nerve activity are due to the fact that the postganglionic fibers of 
these two divisions release different neurotransmitters. 
• The preganglionic neurons in both sympathetic and parasympathetic divisions 
release acetylcholine. 
• The postganglionic parasympathetic neurons release acetylcholine; and the 
postganglionic sympathetic release noradrenaline. 
• The receptors that respond to acetylcholine are classified as nicotinic and 
muscarinic, and those that respond to noradrenaline or adrenaline as a-and p-
adrenergic types. 
• The adrenal medulla is a hormone-secreting part of the sympathetic nervous 
system located above the kidney and secretes mainly adrenaline (Vander, 
Sherman et al. 2001). 
3 
The hypothalamus is the major control and integration center of the ANS. 
Output from the hypothalamus influences autonomic centers in the medulla 
oblongata and spinal cord. It regulates the cardiovascular system, especially the 
control of heart rate and blood pressure. 
1.2.2 The Role of Baroreceptors in the Control of Circulation 
The blood pressure in the circulation is sensed by baroreceptors located in the 
walls of some of the major vessels (Figure 2，page 5). Nerve cells capable of 
responding to changes in pressure or stretch are called baroreceptors. Baroreceptors 
in the walls of the arteries, veins, and right atrium monitor blood pressure. The three 
most important negative feedback systems that baroreceptors participate in are the 
aortic reflex, carotid sinus reflex, and right heart reflex. 
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Figure 2 Position of the main groups of arterial baroreceptors. 
The primary baroreceptors are the arterial baroreceptors, located in the two 
carotid sinuses and the aortic arch. The carotid sinus reflex helps maintain normal 
blood pressure in the brain. Any increase in blood pressure stretches the wall of the 
aorta and carotid sinus, stimulating the baroreceptors. The aortic reflex governs 
systemic blood pressure. The ability of the aortic and carotid sinus reflexes to 
correct a drop in blood pressure is very important when a person sits or stands from a 
recumbent position. The atrial reflex responds to increases in venous blood pressure. 
When venous pressure increases, the baroreceptors send impulses through the vagus 
nerves to the cardiovascular center. Returning impulses via sympathetic nerves 
increase heart rate and force of contraction (Tortora and Grabowski 1996). 
5 
Nonarterial baroreceptors are located in the systemic veins, pulmonary 
vessels, and myocardium. The activation frequency of the arterial baroreceptors is 
proportional to mean arterial pressure and to pulse pressure (Vander, Sherman et al. 
2001). 
The primary integration center for the baroreceptor reflexes is a diffuse 
network of highly interconnected neurons known as the medullary cardiovascular 
center, located in the brainstem medulla oblongata. The neurons in this center 
receive input from the baroreceptors. Baroreceptor information to the medulla 
oblongata stimulates sympathetic and inhibits parasympathetic nerve activity, 
resulting in increased heart rate (HR) and vasoconstriction. 
The baroreceptor reflex can also mediate the opposite response. When blood 
pressure rises above an individual's normal range, the baroreceptor reflex causes a 
slowing of the heart rate and vasodilatation due to decreased sympathetic and 
increased parasympathetic nerve activity (Figure 3，page 7). Additionally, the renin-
angiotensin system senses blood pressure fluctuation and, through the action of 
angiotensin II，plays the role of the guardian of overall peripheral vascular resistance. 
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Figure 3 Schematic diagram of cardiovascular system. 
Schematic diagram of cardiovascular system. BP affects, through baroreceptors and 
central nervous system, both interval length and peripheral resistance (baroreflex). 
Dashed line indicates slow sympathetic control. Cardiac output is determined by HR 
(or RR interval). Peripheral resistance and cardiac output determine new BP value. 
These simulations suggest that respiration first affects BP possibly through 
mechanical effects (De Boer, Karemarker et al. 1987). 
1.2.3 The Control and Physiological Importance of Heart Rate 
1,2,3,1 Normal Heart Rate 
Resting heart rate varies widely in different individuals. During various 
physiological stresses, particularly exercise, it can increase up to three-fold. Heart 
rate is dependent, among other things, on the individual's level of physical fitness. 
Highly trained endurance athletes, for example, have resting levels of HR that, in 
some people, may indicate the need for permanent pacemaker implantation. 
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Heart rate is normally determined by the rate of depolarization of the cardiac 
pacemaker located in the sinoatrial (SA) node. If, for any reason, the normal 
pacemaker fails to generate an impulse, pacemaker tissues elsewhere usually take 
over. 
1.2,3,2 Autonomic Control of Heart Rate 
The intrinsic HR, in the absence of any neurohumoral influence, is about 100-
120 bpm. In the intact, an individual without heart block, the HR at any time 
represents the net effect of the parasympathetic (vagus) nerves that reduce it and the 
sympathetic nerves that accelerate it. In resting conditions, both autonomic divisions 
are thought to be tonically active with the vagal effects dominant. 
1.2.3.2.1 Sympathetic Effects 
Sympathetic postganglionic fibers innervate the entire heart, including the 
sinoatrial node, the atrioventricular (AV) conducting pathways, and the atrial and 
ventricular myocardium. Increased sympathetic activity results in increases in both 
HR and the force of contraction. Additionally, the propagation velocity of the cardiac 
impulse increased and the systolic duration decreased. 
An increase in sympathetic activity forms the principal method of increasing 
HR above the intrinsic level generated by the SA node (about 110 bpm). Following 
the onset of sympathetic stimulation, there is a latent period of up to 5 seconds 
followed by a progressive increase in HR, which reaches a steady level in 20-30 
seconds. In contrast, vagal responses are almost instantaneous. Both sympathetic 
efferent and parasympathetic activity have a nonlinear relationship to HR. 
1.2.3.2.2 Vagal Effects 
The vagal nerves innervate the SA node, the AV conduction pathways, and 
the atrial muscle. Controversy exists over whether the vagus nerve provides efferent 
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control to ventricular muscle. It may be that apparent depression of ventricular 
contraction by vagal stimulation reported in some studies may have been at least 
partly the result of decreased diastolic ventricular filling subsequent to atrial 
depression. 
The most obvious effect of vagal stimulation is to slow, or even stop, the 
heart. The latency of the sinus response is very short, and the effect of a single vagal 
impulse depends on the phase of the cardiac cycle at which it is applied. The 
maximum response has been reported to occur only 400ms after a single vagal 
stimulus. Thus, vagal stimulation results in a peak response in the first or second 
beat after its onset. After cessation of vagal stimulation, HR rapidly returns to its 
previous level. The speed of recovery is a little slower than that of the onset, but the 
initial HR is usually restored in less than 5 seconds. 
The frequency of vagal stimulation is proportional to the amount of slowing 
of HR. Maximal change in HR is observed at frequencies of up to 5 Hz. The 
relationship between the change in HR and stimulus frequency is hyperbolic. The 
gross nonlinearity of this relationship suggests that HR may not be an appropriate 
variable to measure when quantifying efferent autonomic effects. If R-R interval 
(pulse-interval), which is a function of the reciprocal of HR, is plotted against 
stimulus frequency, the relationship becomes linear. 
L 2,3,3 Reflexes Influencing Heart Rate 
Heart rate, at any instant in time, represents the net result of many influences 
on the vagal and sympathetic centers (Table 1, page 10). Some reflexes may increase 
HR through a decrease in vagal tone, an increase in sympathetic activity, or both. 
Other reflexes exert the opposite effects. In an individual, several reflexes are likely 
to operate simultaneously and, for some of these, the interactions may be quite 
complex. 
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Table 1 Reflexes Influencing Heart Rate 
Reflexes Causing Bradycardia Reflexes Causing Tachycardia  
Baroreceptors Atrial receptors  
Carotid chemoreceptors Aortic chemoreceptors ^  
Coronary chemoreflex (Bezold-Jarisch) Muscle receptors  
Lung hyperinflation Lung inflation (moderate)  
1.2.3.3.1 Baroreceptors 
An increase in blood pressure stretches these vessels and results in increased 
in discharge frequency in their afferent nerves. This discharge increases abruptly but 
then rapidly adapts to a rate, which may be only moderately raised. 
Stimulation of baroreceptors results in an increase in efferent cardiac vagal 
activity with a concomitant decrease in sympathetic activity (Figure 3, page 7). As 
the response of the sinoatrial node to vagal stimulation is very rapid, much of the 
latency of the HR response to a carotid sinus stimulus is due to the time of the reflex 
propagation. 
The effects of baroreceptor inhibition depend on the present levels of 
autonomic activity. For example, if HR is fast due to a low level of vagal activity 
and a high level of sympathetic activity, baroreceptor inhibition of vagal activity 
would have a proportionally smaller effect than when HR was slow. 
1.2.3.3.2 Chemoreceptors 
Chemoreceptors monitor chemical levels in the blood. Peripheral arterial 
chemoreceptors are situated in the carotid and aortic bodies. The most obvious 
effects of chemoreceptor stimulation are increases in the rate and volume of 
respiration. 
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Like baroreceptors, chemoreceptors also influence HR, but in different 
directions. As HR is also influenced by respiratory effort, the effect of 
chemoreceptor stimulation upon HR may be masked by the secondary effects of the 
respiratory response. If respiration is controlled, stopped or the lung denervated, 
carotid chemoreceptor stimulation causes a large and consistent bradycardia. 
Aortic body chemoreceptors also stimulate respiration, but paradoxically, the 
primary effect on the heart is excitatory. The reason for this effect is unknown. 
1.2.3.3.3 Atrial Receptors 
Atrial Receptors are concentrated near the junctions of the superior and 
inferior vena cava and the pulmonary veins with the atria. They are stimulated by 
stretching due to increased atrial volume, but some are also excited by atrial 
contraction. Their discharge frequency is directly related to right atrial pressure. 
Atrial baroreceptors increase HR in response to an increased venous return, a process 
known as the Bainbridge reflex. 
1.2.3.3.4 Coronary Chemoreflex 
Injections of many substances into the coronary circulation may result in 
bradycardia and hypotension. Chemicals causing this response include phenyl 
diguanide and capsaicin, as well as substances resulting from myocardial ischemia 
including bradykinin and prostaglandins. 
Additionally, some chemosensitive nerves from the heart accompany the 
sympathetic nerves and are believed to cause excitatory responses including 
increases in HR. They may contribute to the increases in HR and blood pressure that 
sometimes occur with myocardial ischemia and infarction, particularly when this 
involves the anterior wall of the heart. 
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1.2.3.3.5 Other Reflexes 
Almost all parts of the body, when subjected to intense or noxious stimuli, 
may result in cardiovascular reflexes. Lung inflation, with moderate pressures, 
stimulates airway stretch receptors, which are attached to myelinated nerves. This 
results in a reflex increase in HR. 
Stretch receptors also exist in the wall of the pulmonary artery and are 
excited by increases in pulmonary arterial pressure. The reflex response is an 
increase in vascular resistance, which has an indirect effect upon HR. 
The abdominal viscera are richly supplied with afferent nerves and the 
activity in these increases in response to venous congestion. The resulting reflex is 
to increase sympathetic activity to the circulation, leading to hypertension and 
tachycardia. 
1.2,3.4 Influence of Complex Events on Heart Rate 
1.2.3.4.1 Respiratory Influence 
Sinus Arrhythmia 
This refers to the cyclical variation in HR associated with respiration. Heart 
rate accelerates during inspiration and slows during expiration. The magnitude of 
this oscillation is variable, but can usually be exaggerated by slow deep breathing. 
The mechanism linking variability of HR to respiration is complex and involves both 
central and reflex interactions. Sinus arrhythmia is mostly, if not entirely, mediated 
through changes in efferent vagal activity. The magnitude of the variation of sinus 
rhythm is claimed to provide an index of the level of efferent vagal activity to the 
heart. 
Valsalva Maneuver 
The subject takes a large inspiration followed by a maximal expiratory effort 
against an obstruction. This procedure generates an intrathoracic pressure in the 
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order of 100 mm Hg. This is transmitted to the intrathoracic and intra-abdominal 
blood vessels and initially increases arterial pressure (AP). Impaired venous return 
from outside the thoracoabdominal region causes a decrease in cardiac output and 
blood pressure. This leads to a decrease in baroreceptor activity, resulting in reflex 
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increases in HR and vascular resistance and a restoration of mean AP, although not 
pulse pressure. On release of the Valsalva, venous return from the region outside the 
thorax and abdomen is initially enhanced leading to a marked increase of blood 
pressure and a baroreflex-mediated bradycardia. 
1.2.3.4.2 Effects of Decreases in Venous Return 
Venous return is reduced when blood volume is decreased due to hemorrhage 
or other causes of hypovolemia. It is also low if there is excessive pooling of blood 
in peripheral vessels during postural stress. 
There are three phases of responses of the cardiovascular system to decrease 
venous return. Initially, blood pressure remains little changed, or even increased. 
This is associated with increases in vascular resistance and heart rate. Secondly, 
blood pressure may fall, despite further increases in vascular resistance and HR. 
Finally, there may be an abrupt fall in blood pressure and loss of consciousness. 
This severe hypotensive phase is concomitant to a decrease in vascular resistance and 
often also in HR, and is termed a vasovagal reaction. Moderate orthostatic stress 
results in decreases in cardiac output and in cardiac filling pressure accompanied by 
tachycardia, but not hypotension. 
1.2.3.4.3 Exercise 
Immediately at the onset of exercise, there is an increase in HR, which, as 
shown by its rapid onset, is due to parasympathetic inhibition. The immediate 
response is attributed to central command. Metaboreceptors within the muscle also 
become stimulated and these contribute to a sympathetic afferent input, which further 
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increase HR. Many other mechanisms are also involved, including reflexes from 
lung inflation and possible inhibition of the baroreceptor reflex. 
L 2,3,5 Physiological Importance of Heart Rate 
The importance of HR lies in its contribution to cardiac output: 
Cardiac output = stroke volume x HR. 
However, this equation can be misleading. This is because stroke volume 
and HR are not independent. Particularly, changes in HR are liable to result in 
reciprocal changes in stroke volume. 
A number of studies have concurred that, at rest, changes in HR between 
approximately 80 and 150 bpm have little effect on cardiac output as an increase in 
rate is almost exactly counteracted by a corresponding reduction in stroke volume. 
Below 50 bpm stroke volume tends to be fixed and changes in HR then result in 
proportional changes in flow. 
1.3 Spectral Analysis of Blood Pressure and Heart Rate Variability 
in Evaluating Cardiovascular Regulation 
The regulation of BP is traditionally described in terms of homeostasis. It 
indicates the BP, although being continuously perturbed by external stimulations, 
always displays the tendency to come back toward a reference attention should be 
directed not only to the average BP value, which can be regarded as the reference set 
point, but also to the BP and cardiovascular fluctuations occurring around this 
average. Data from a variety of sources indicate that these fluctuations are indeed 
much more than undesirable noise. On the contrary, they represent a rich source of 
information that can provide considerable insight into the mechanisms of 
cardiovascular control (Malliani, Pagani et al. 1991). Cardiovascular fluctuations 
can be studied through beat-to beat BP and HR monitoring and calculation of the 
variance (or standard deviation) of their average values. However, frequency 
domain analysis has also been used to subdivide the variability of BP and HR into 
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different frequency components and to quantify the variance or ‘power，at each 
specific frequency. Blood pressure variability includes rhythmic and nonrhythmic 
fluctuations that, with the use of spectral analysis, appear as clear peaks or 
broadband power, respectively. The assessment of HRV, alone or in combination 
with the analysis of BP variability, offers valuable information on the mechanisms 
responsible for cardiovascular regulation. 
1.4 Clinical Relevance 
1.4.1 Increased Sympathetic Activity 
There is a wealth of experimental evidence linking abnormalities of the ANS 
to ventricular arrhythmias during myocardial ischemia or CHF. Noradrenaline is 
reflexively released from sympathetic nerve terminals to maintain blood pressure in 
response to decreased cardiac output. However, this also acts to stimulate ventricular 
arrhythmias, through a variety of mechanisms. Ventricular arrhythmias are accepted 
as significant risk factors for sudden death in patients with ischemic or nonischemic 
heart failure. Factors that increase sympathetic nervous system activity increase the 
likelihood of ventricular arrhythmias, whereas those that decrease sympathetic 
nervous system activity decrease the likelihood of ventricular arrhythmias. 
Conversely, an increase in parasympathetic nervous system activity suppresses 
arrhythmias whereas a decrease in its activity tends to promote them (Bosher and 
Kleiger 1995). 
1.4.2 Reduced Parasympathetic Activity 
The weight of evidence indicates that cardiac parasympathetic function is 
markedly depressed in patients prone to development of sudden cardiac death (SCD) 
and that this, and possibly other, alterations in autonomic balance are important 
contributors to the development of electrical instability in such individuals. Major 
risk factors for SCD, including coronary artery disease, MI, congestive heart failure, 
and hypertension, all have been associated with reduced parasympathetic activity. 
The reasons for the deleterious effects of reduced parasympathetic activity are 
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unknown. One hypothesis is that vagal withdrawal reduces or abolishes the ability to 
counter the potentially arrhythmogenic effects of sympathetic activity. 
1.4.3 Low Heart Rate Variability 
/ 
It has been known for many years that reduced HRV reflects autonomic 
function. During the 1970s a number of simple bedside tests were used to detect 
diabetic autonomic neuropathy and in 1978 Wolf et al showed that mortality after 
myocardial infarction was associated with reduced HRV (Wolf, Varigos et al. 1978). 
Kleiger reported that post myocardial infarction (MI) patients with decreased HRV 
(standard deviation of normal-normal, SDNN of <50 mms) have decreased vagal tone 
or increased sympathetic tone demonstrating higher risk for ventricular fibrillation 
(Anonymous 1992). 
It is not surprising therefore that HRV has been shown to be a powerful 
independent predictor of all cause mortality in the post MI population, as well as in 
patients with a number of no cardiac disease states. It was also found to be the single 
best predictor of major arrhythmic events, including ventricular fibrillation and SCD 
in post MI patients. 
HRV is markedly depressed in survivors of adverse cardiac events compared 
with normal controls, particularly in patients found to have inducible ventricular 
tachyarrhythmias at invasive electrophysiological study. This patient population 
appears to be at very high risk of a second episode of SCD. The combination of low 
HRV and inducibility correctly identified all SCD survivors who subsequently died 
during a 100-month follow up (Singer and Ori 1995). 
HRV also may be low in patients with asymptomatic, complex ventricular 
ectopic who develop sustained ventricular tachycardia during programmed 
ventricular stimulation, and the degree of reduction is similar to that found in SCD 
survivors. In contrast, subjects with non-inducible asymptomatic complex 
ventricular ectopic had a somewhat diminished HRV, but at a level which did not 
differ statistically from normal. 
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Decreased HRV in heart failure patients has now been found in several studies 
(see below). This has a complex etiology but in part it may reflect the progressive 
loss of the neural modulation of HR that is caused by a progressive increase of 
plasma catecholamine levels (Casolo 1995). 
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1.4.4 Depressed Baroreflex Sensitivity 
Researchers have found that analysis of the baroreflex sensitivity (BRS) can 
identify subgroups at both lower and higher risk for sudden death. Specifically, it has 
been found that depressed baroreflex sensitivity is associated with a higher risk of 
developing ventricular fibrillation during acute myocardial ischemia. Depressed 
baroreceptor function is early feature that may precede the onset of clinically obvious 
signs and symptoms of congestive heart failure (Eckberg, Drabinsky et al. 1971; 
Ferguson, Abboud et al. 1984; Porter, Eckberg et al. 1990; Creager and Creager 
1994). 
1.4.5 Prognostic Value of Heart Rate Variability in Disease States 
As noted above in 1978, Wolf et al. showed that a high risk of mortality after 
MI was associated with reduced HRV (Wolfe, Varigos et al. 1978). Kleiger et.al. 
(Kleiger, Miller et al. 1987) measured 24-hour HRV, 11 士 3 days post-MI, and 
demonstrated that a reduction in HRV (SDNN <50 ms) was associated with an 
increase in mortality rate of 5.3 times compared to patients with a SDNN >100 ms in 
the first 4 years following ML The UK-HEART investigators examined the value of 
HRV measures as independent predictors of death in CHF and found that a reduction 
in SDNN was the most powerful predictor of death (Nolan, Batin et al. 1998). 
1.4.6 Abnormality of Autonomic Nervous System in Heart Failure 
Abnormalities of the autonomic nervous system are recognized to be part of 
the syndrome of CHF (Eckberg, Drabinsky et al. 1971; Ferguson, Abboud et al. 
1984; Porter, Eckberg et al. 1990). Activation of the sympathetic nervous system, 
decreased activity of the parasympathetic nervous system and depressed baroreceptor 
17 
function are early features that may precede the onset of clinically obvious symptoms 
and signs of heart failure (Eckberg, Drabinsky et al. 1971; Ferguson, Abboud et al. 
1984; Porter, Eckberg et al. 1990; Creager and Creager 1994). Increased 
sympathetic activity is a recognized feature of heart failure (Thomas and Marks 
1978; Cohn, Levine et al. 1984; Leimbach, Wallin et al. 1986). Although initially 
supporting the failing heart, prolonged excessive activation of the sympathetic 
nervous system has many potential adverse effects including a direct cytotoxic 
action on myocardial cells, promotion of arrhythmias, decreased coronary blood 
flow, excessive vasoconstriction reducing tissue perfusion, and stimulation of 
myocardial collagen formation (Van Vliet, Burchell et al. 1966; Podrid, Fuchs et al. 
1990; Bhambi and Eghbali 1991). Plasma noradrenaline, which is an index of 
sympathetic activity, is increased in heart failure and has been shown to be a 
powerful predictor of mortality (Cohn, Levine et al. 1984; Benedict, Shelton et al. 
1996). However, the plasma levels reflect not only neuronal release but also 
variations in re-uptake and metabolism (Masking, Esler et al. 1986). 
Microneurographic recording of efferent postganglionic nerve activity have shown 
that heart failure patients are characterized by a resting muscle sympathetic nerve 
activity that is markedly greater than that displayed by age-matched normal subjects 
(Leimbach, Wallin et al. 1986). This is true whether the data is expressed as burst 
frequency over time or when it is corrected for the accompanying heart rate values to 
account for a possible increase in nerve traffic due to heart failure related 
tachycardia. The magnitude of the muscle nerve sympathetic activation correlates 
directly with the severity of the symptoms and inversely with measures of left 
ventricular function such as the ejection fraction (Grassi，Seraville et al. 1995). 
Furthermore, activation of the sympathetic nervous system is an early phenomenon 
in heart failure (Grassi, Seraville et al. 1995). 
Heart failure is also characterized by reduced vagal activity. In experimental 
studies there is rapid withdrawal of parasympathetic activity, which occurs in parallel 
with the decline in left ventricular contractility. (Ishise, Asanoi et al. 1998) 
A simple non-invasive test which would provide a measurement of 
sympathetic activation and parasympathetic inhibition and, if possible, a measure of 
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baroreceptor function, would be extremely useful in patients with heart failure. 




2 METHODS FOR ASSESSING HEART RATE VARIABILITY 
/ 
HRV, since its first description by Hales in 1733 and the clinical utilization by 
Hon and Lee in 1963 (Hon and Lee 1963)，has been intensively studied for over three 
decades. There are several approaches in the evaluation of HRV. The most 
frequently used technologies are the time and frequency domain analyses. 
2.1 Time Domain Analysis of Heart Rate Variability 
Time domain analysis calculates a number of parameters that describe either 
the heart rate at any time or the interval between successive normal cardiac cycles. 
In a continuous electrocardiographic recording, each QRS complex is detected, and 
the normal-to normal (NN) intervals or the instantaneous heart rate is determined. 
HRV is assessed on the basis of variability of sinus rhythm. Thus recordings 
with frequent ectopics and missed beats, pauses, arrhythmias, and noise must be 
manually edited and corrected. 
A large number of variables can be measured once beat-to-beat intervals are 
measured (Table 2，page 21). Essentially there are two types of measurements those 
derived directly from the intervals themselves and secondly those based on the 
differences between adjacent cycles. 
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Table 2 Definitions for Time Domain Measures of Heart Rate Variability 
Variable Domain Units Definition 
Night/day difference time msec Difference between the average of all the normal 
RR intervals at night and the average of all the 
normal RR intervals during the day 
CLV time msec Standard deviation of all normal RR intervals in 
the entire 24-hr ECG recording (Also referred to 
as SDRR or SDNN) 
SDANN time msec Standard deviation of the mean of normal RR 
intervals for each 5 min period of the 24 hr ECG 
recording 
SDNNIDX time msec Mean of the standard deviations of all normal RR 
intervals for all 5 min segments of a 24-hr ECG 
recording 
pNN50 time % Percent of difference between adjacent normal 
RR intervals that are greater than 50 msec, 
computed over the entire 24-hr ECG recording 
r-MSSD time msec Root mean square successive difference, the 
square root of the mean of the sum of the squares 
of differences between adjacent normal RR 
intervals over the entire 24-hr ECG recording 
SDSD time msec The standard deviation of successive differences 
between adjoining normal cycles 
Counts time beats The number of time that the difference between 
adjacent normal RR intervals is greater than 50 
msec, computer over the entire 24 hr recording 
2.1.1 Statistical Methods 
(Table 2，page21) 
The simplest way to analyze the variability in heart rate is to measure the 
time difference between each beat and the next and to compare this measurement to 
the instantaneous heart rate and the normal to normal (NN) interval, calculated over 
24 hours, and its standard deviation (SDNN). 
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The mean NN interval is computed by selecting coupling intervals that 
contain no ectopic beats or noise, and do not exceed a user-specified longest and 
shortest NN interval. Both atrial and ventricular ectopic are excluded. The standard 
deviation of the average NN intervals (SDANN) is a mathematical extension of this, 
calculated over short intervals, usually five minutes, and the SDNN index, which is 
the mean of the standard deviation of the five-minute NN intervals calculated over 
24 hours. 
Examples of the second type of measurement are the rMSSD, the root mean 
square of differences in successive NN intervals. The NN50, a count of the pairs of 
successive NN intervals that differ by 50ms or more, and pNN50 (NN50 divided by 
total NN intervals). 
These time-domain measurement methods can be applied to any recording 
ranging from the very short (e.g. 5 min) to the very long (e.g. 24-48 hours). Time-
Domain methods are preferable to spectral analysis (discussed below), when the 
subjects are non-stationary or the recordings contain too many ectopic beats, which 
would require interpolation that would invalidate the detailed spectral methods. 
2.1.2 Geometric Methods 
The HRV triangular index (an approximation of the area under the curve of 
RR interval variability) has been widely used, especially in post-MI patients (Malik, 
Farrell et al. 1989). This measure reflects the lower frequency variations more than 
higher frequencies. This index is only approximate and is not as precise as the 
values provided by the statistical and spectral methods. 
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2.2 Spectral Analysis of Heart Rate Variability 
Spectral analysis attempts to characterize mathematically the physiologic 
mechanisms that produce variations in R-R intervals. This method calculates the 
frequency content of time-varying signals, offering a breakdown of successive R-R 
intervals to their frequency components (Akselrod, Gordon et al. 1981; Rottman， 
Steinman et al. 1990). From the earliest studies it was clear that the HRV signal 
contains well-defined rhythms which contain physiological information. 
The most obvious quantity to measure for any rhythmic phenomenon is the 
time taken for one cycle, termed the period. Another way to describe rhythmic 
phenomenon is to express its frequency. Measurement of frequency is in Hertz (Hz). 
One cycle per second is thus 1 Hz, an average heart rate (72 beats per minute) is 1.2 
Hz, and respiration (15 breaths per minute) has an average frequency of 0.25 Hz 
(Anonymous 1992). 
In the frequency domain, two methods of calculating power spectral density 
have been used; those based on a Fourier analysis, and autoregressive spectra 
(Anonymous 1996). The Fourier analysis, provided by a Fast Fourier Transform 
(FFT), describes a signal as the sum of several sinusoids at fixed and equally spaced 
frequencies; i.e., the output of several sinusoidal oscillators, the amplitudes and 
phases of which are described by the FFT. FFT utilizes fast and simple algorithms 
available in most mathematical libraries. Autoregressive methods provide smoother 
spectral components, thereby allowing easier identification of the frequency bands 
and automatic calculation of frequency power. 
Recordings are done over short intervals, typically five minutes. Three major 
components are apparent: very low frequency (VLF, range: 0.0033-0.4 Hz), low 
frequency (LF, range: 0.04-0.15 Hz) and high frequency (HF range: 0.15-0.4 Hz). 
In early studies, it was suggested that the HF component represented vagal activity 
and LF was a marker of sympathetic modulation. Thus, the ratio LF: HF was thought 
to reflect autonomic balance, which became more obvious when normalized units are 
used (Pagani, Lombardi et al. 1986; Malliani, Pagani et al. 1991). Although it is 
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generally recognized that the HF component does, to some extent, represent vagal 
activity, there is considerable debate about the origin of the LF component, 
especially in heart failure. 
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If normalized units are used, a clear increase in LF power can be seen in 
normal subjects with passive tilting (Figure 4, page 25), mental stress, and moderate 
exercise. This finding was used originally as evidence that the LF component of R-R 
variability represents sympathetic activity (Montano, Gnecchi-Ruscone et al. 1994). 
However, recently Eckberg has criticized the use of spectral analysis to assess 
sympatho-vagal balance (Eckberg 1997). Pointing out that vagal contribution to 
baseline LF R-R interval fluctuations are great, as indicated by the effect of atropine 
on the LF component, he concludes there is no evidence that baseline LF R-R 
spectral power is quantitatively correlated with sympathetic cardiac nerve traffic 
(Eckberg 1997). However, Bemardi et al (Bemardi, Bianchini et al. 1995) showed 
that sympathetic reinnervation in transplanted hearts was associated with non-
respiratory LF. Pagani et al (Pagani, Montano et al. 1997) reported a very tight 
correlation between LF normalized units of RR and LF nu of muscle sympathetic 
nerve activity (MSNA) variability. 
24 
Rest Tilt  
！ \ LF 
i . u l : 
OL 0'‘——‘ ‘ I 丨 乂 I iZ i 
0 0.5 0 0-5 Hz Hz 
Total variance 2000 ms^ Total variance 633 i W 
LF = 573 i W • 52-84 nu LF = 303 ms^ « 74.34 nu 
HF : 491 ms^ • 45.32 nu HF : 93 ms^ - 22-85 nu 
Figure 4 Example of spectral analysis of RR interval variability in a healthy 
subject examined at rest and during a passive tilt. 
At rest, there are two major components (LF and HF) of similar power, whereas 
during tilting the LF component predominates. In this case, the total variance during 
tilting is markedly reduced, so both LF and HF powers are diminished when 
expressed in absolute units. The use of normalized units (nu) clearly indicates the 
altered relation between the two spectral components induced by tilting. The pie 
charts show this relative distribution together with the absolute power of the two 
components (represented by the area) (Malliani, Lombardi et al. 1994). 
Furthermore, although a quantitative relation does exist between HF R-R 
interval spectral power and vagal cardiac activity (Kollai and Mizsei 1990), this 
index is not perfect. The large change of HF power induced by changes in 
respiration (which are rarely controlled for) may not reflect changes in vagal cardiac 
activity, but may merely be reflecting the kinetics of sino-atrial node responses to 
acetylcholine (Saul, Berger et al. 1991). A reasonable correlation may exist between 
HF-RR-interval variability and vagal activity only when respiration is controlled 
(Eckberg 1997). 
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Bemardi et al. (Bemardi, Leuzzi et al. 1994) have produced evidence to 
support the hypothesis that the LF component of RR variability may be generated 
from baroreceptor-sensed blood pressure fluctuations. This hypothesis is based on 
the thesis of DeBoer et al (De Boer, Karemarker et al. 1987) and Madwed et al 
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(Madwed, Albrecht et al. 1989) that suggests that LF oscillation is due to the phase 
lag in the baroreceptor loop. Respiration leads to changes in the venous return to the 
right heart, enhancing the stroke volume in the left heart, which in turn determines 
the respiratory-related changes in blood pressure. These changes stimulate the 
baroreceptors, which cause a fast (<1 second) vagal response to the heart and a slow 
sympathetic withdrawal (3-10 second) to the blood vessel. Due to the delay in 
sympathetic withdrawal, it is out of phase with the initial perturbation, and thus, 
instead of buffering it, leads to a new oscillation that is in turn sensed by the 
receptors and so on. This new oscillation is therefore more dependent on the delay 
of the overall response rather than on the initial stimulus. Mathematically this is 
likely to be in the range of the low frequency component. This theory would also 
explain why atropine abolishes most of the LF as well as the HF components. It is 
likely, therefore, that the LF component is at least partly dependent on baroreceptor 
function and that this dependence is centrally modulated. 
The exact physiological mechanisms underlying the ultra low frequency 
(ULF) and VLF components, which account for nearly 90% of total power are still 
unknown (Anonymous 1996). Measurements of VLF require long-term recordings. 
Post myocardial infarction ULF and VLF appear to have strong prognostic predictive 
value (Malik, Farrell et al. 1989; Malliani, Pagani et al. 1991; Anonymous 1996). 
Use of spectral analysis of HRV to assess baroreceptor function 
Several quantitative approaches have been developed for evaluating 
baroreflex sensitivity, including the analysis of reflex responses to pharmacological 
and mechanical manipulations of baroreceptors and the analysis of spontaneously 
occurring changes in blood pressure and heart rate. 
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However, arterial baroreflex sensitivity has been assessed by spectral analysis 
using the "a-angle" method (Malliani, Pagani et al. 1991). The gain of the arterial 
baroreflex was obtained by dividing the amount of fluctuation in the R-R interval by 
the fluctuations of systolic blood pressure (SBP) at the same frequency. A 
mathematical function (squared coherence) was used to prove that fluctuations in the 
R-R interval are in fact related to similar fluctuations in blood pressure. This 
approach gives results comparable to those obtained with the Oxford phenylephrine 
test. 
When the coherence in cross spectrum between R-R and SBP was > 0.5 the a 
index (the square root of the ratio of the RR and SBP power in HF or LF bands) can 
be calculated for LF and HF (Figure 9，page 58). In heart failure subjects LF power 
is much reduced and it is not possible to calculate a LF in most patients. Thus a HF, 
which is at the respiratory frequency, can be used as the index of baroreceptor 
function. 
2.3 Nonlinear Indices (fractal，entropy, chaos theory) 
(Goldberger, Rigney et al. 1990) 
A number of other approaches have been applied to RR variability. 
Mathematical complexity, they are unlikely at present to be clinically useful, but may 
become so. Intuitively, it seems likely that these nonlinear methods will be more 
suitable for biological variables like heart rate or blood pressure, although there is 
some doubt about the applicability of chaos theory to HRV (Le Pape, Giacomini et 
al. 1997). 
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3 HEART FAILURE 
3.1 Heart Rate Variability in Heart Failure 
Results of HRV analyses in heart failure patients 
A considerable body of evidence now confirms the fact that in heart failure, 
sympathetic activity is increased, parasympathetic activity decreased and that this is 
associated with depression of baroreceptor function (Eckberg, Drabinsky et al. 1971; 
Porter, Eckberg et al. 1990; Creager and Creager 1994; Ferguson and Mark 1994). 
Are these changes reflected in HRV analysis? (Table 3，page 30) summarizes the 
results of the major studies on HRV in heart failure. Nearly all these studies confirm 
that HRV is greatly reduced in heart failure and that this is related to the severity as 
assessed by NYHA class or LVEF. 
Through the using spectral analysis, the HF component has been shown to be 
lower, which is in keeping with reduced parasympathetic activity. However, the LF 
component is variable. In most studies, the LF component is reduced or absent, but 
Guzzetti et al (Guzzetti, Cogliati et al. 1995) showed that the LF component is 
increased in those patients with mild and NYHA class II heart failure but absent in 
those with NYHA class IV symptoms. 
Mortara et al also demonstrated a worse prognosis in those with an absent 
(Mortara, La Rovere et al. 1994) LF component. If the LF component is indeed 
reflecting sympathetic activity, then one would expect this component to increase in 
patients with more severe heart failure, and therefore the absence of the LF 
component is paradoxical. Indeed, Kingwell et al (Kingwell, Thompson et al. 1994) 
who has demonstrated a disparity between cardiac noradrenaline spillover, which is 
elevated in cardiac failure patients, at the same time that 0.1 Hz HRV was reduced. 
However, the largest study in heart failure was the UK-HEART which 
examined the value of HRV measures as independent predictors of death in CHF 
(Nolan, Batin et al. 1998). In this prospective study powered for mortality, 433 out-
patients 62±9.6 years old with CHF (NYHA functional class I to III; mean ejection 
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fraction, 0.41 士0.17) were recruited. Time-domain HRV indices and conventional 
prognostic indicators were related to death by multivariate analysis. During 482±161 
days of follow-up, cardiothoracic ratio, SDNN, left ventricular end-systolic diameter, 
and serum sodium were significant predictors of all-cause mortality. The risk ratio 
/ 
for a 41.2-ms decrease in SDNN was 1.62 (95% CI, 1.16 to 2.44). The annual 
mortality rate for the study population in SDNN subgroups was 5.5% for >100 ms, 
12.7% for 50 to 100 ms, and 51,4% for <50 ms. SDNN, creatinine, and serum 
sodium were related to progressive heart failure death. Cardiothoracic ratio, left 
ventricular end-diastolic diameter, the presence of nonsustained ventricular 
tachycardia，and serum potassium were related to sudden cardiac death. A reduction 
in SDNN was the most powerful predictor of the risk of death due to progressive 
heart failure. The authors concluded that CHF is associated with autonomic 
dysfiinction, which can be quantified by measuring HRV. A reduction in SDNN 
identifies patients at high risk of death and is a better predictor of death due to 
progressive heart failure than other conventional clinical measurements. High-risk 
subgroups identified by this measurement are candidates for additional therapy after 
prescription of an ACE inhibitor. 
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Table 3 Heart Rate Variability Studies - Heart Failure (1988 - 2002) 
Author of Study Population Method Findings 
(Saul, Arai et al. 25 chronic CHF Spectral Blackman-Tukey Spectral power reduced all 
1988) 21 normals 15-min acquisition frequencies,  
especially > 0.04 Hz  
(Casolo, Balli et 20 CHF Time domain RR interval Low HRV 
al. 1989) 20 normals histogram with 24-h 
Holter  
(Binkley, 10 dilated Spectral FFT Reduced HF power (>0.1 Hz) 
Nunziata et al. cardiomyopathy 4-min supine acquisition 
1991) 10 nomrals 
(Coumel, 13 CHF nonspectral Depressed HRV 
Hermida et al. 
1991 ) 
(Kienzle， 23 CHF Spectral FFT Time Alterations of HRV not tightly 
Ferguson et al. Domain linked to severity 
1992) 24-48-h Holter of CHF I HRV was related to 
sympathetic 
excitation  
(Fei, Keeling et 40 CHF -
al. 1994) 15 controls Spectral Reduced TP, LF, HF related to 
15 NSVT (24 hr Amb ECG) LVEF 
(Kingwell, 15 CHF Spectral 
Thompson et al. Microneurography Reduced 0.1 H^ HRV 个 NE 
1994) Cardiac NE Spillover spillover 
(Mortara, La 30 CHF Spectral 14 no LF detectable 
Rovereetal. 13 post (30 mins) 16 increased LF 
1994) transplant worse prognosis in absent LF 
15 controls group 
Poincare plots 
(Woo, Stevenson 21 CHF Time domain Complex plots are associated 
et al. 1994) 24-h Holter with 个 norepinephrine 
levels and greater sympathetic 
activation  
(Casolo, Stroder 80 CHF due to Time domain spectral Decrease in HRV correlated 
et al. 1995) CAD with NYHA class 
(Guzzetti, 30 CHF Spectral (256-512 periods) NYHA Class II 个 LF 
Cogliati et al. 15 controls NYHA Class IV absent LF 
1995 ) 
(Panina, Khot et 20 CHF Spectral/Time domain Suppressed diurnal variation of 
al. 1995) (24 hr Amb ECG) HRV 
(Tanabe, 18 DCM Spectral Higher mean RR, HF lower LF 
Twamoto et al. and LF/HF at 
1995) night relative to day  
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Table 3 Heart Rate Variability Studies 一 Heart Failure (1988 一 2002) 
Cont'd 
Author of Study Population Method Findings 
/ 
(Ponikowski, 36 CHF Spectral Depressed indices of HRV 
Chua et al. 1996) Discrete VLF oscillations in 
RR 
common in CHF 
(Sanderson, 11 CHF Spectral T F T ( a b s e n U n ^ 
Yeung et al. 10 normal Autoregressive Respiratory rate and posture 
1996) affect measurements 
(Butler, Ando et 20 CHF Spectral Total RR power reduced. ~ 
al. 1997) 20 normal Fractal analysis Slope of 1/6 beta relationship 
steeper in CHF 
(Ho, Moody et 69 CHF Spectral SD^ , LF，VLF and TP and 
al. 1997) (24 hr Amb ECG) detrended 
Fluctuation analysis predictors 
of 
Survival (1.9 years) 
(Ponikowski, 26 CHF Spectral HRV (20 min) Peripheral chemosensitivity 
Chua et al. 1997) Baroreflex sensitivity correlated 
and peripheral inversely with HRV power 
chemosensitivity (LF) 
and baroreflex sensitivity  
(Ponikowski, 102 CHF Time domain SDNN, SDANN, SD, LF 
Anker et al. Spectral analysis (24 predictors 
1997) hr Amb ECG) of deaths (Fu 584 土 405 days) 
(Szabo, van 159 CHF Time domain SDNN, pNN50 predicted 
Veldhuisen et al. increase risk 
1997) of cardiac death and death to 
progressive CHF 
(Van de Borne, 21 CHF Spectral Reduced LF in RR and MSNA 
Montano et al. 12 normals microneurography Preserved HF 
1977) close coherence between RR 
and MSNA 
(Nolan, Batin et 433 CHF Time-Domain SDNN was the best predictor 
al. 1998) of mortality  
(Sanderson, 50 CHF Spectral Baseline cxhf was significantly 
Yeung et al. 35 normals Autoregressive depressed in CHF 
1999) compared to normals 
After treatment with 
metoprolol: 
ochf & (RR) HF power 个 
(Bemardi, Porta 81 CHF Spectral Slow breathing induced 个 in 
et al. 2002) 21 normals Autoregressive baroreflex sensitivity  
both in normals and in CHF 
31 
Why is the LF component absent in patients with severe heart failure? 
In normal subjects, the LF component appears to follow sympathetic activity 
in that it increases on standing or with tilting (Montano, Gnecchi-Ruscone et al. 
1994). Recently Pagani et al (Pagani, Montano et al. 1997) have shown that in 
normal subjects, during sympathetic activation there is predominance in the LF 
component of blood pressure, RR interval and muscle sympathetic nerve activity 
(MSNA). 
During sympathetic inhibition, the HF component predominates, and this 
relationship is best seen when power spectral components are normalized for total 
power. Pagani et al (Pagani, Montano et al. 1997) also demonstrated synchronous 
changes in the LF/HF rhythms of both R-R interval and MSNA during different 
levels of sympathetic drive. 
The results suggest that a common central mechanism governs both 
parasympathetic and sympathetic cardiovascular modulation. However, in heart 
failure it has been assumed that the reduced or absent LF component is due to 
saturation of the sinus node or due to down-regulation of (3 receptors (Malik and 
Camm 1993). 
Although the down regulation of (3 receptors in heart failure is an established 
fact (Bristow, Ginsburg et al. 1982) and these receptors have a clear role in HRV in 
normal animals (as demonstrated by the transgenic model (Mansier, Medigue et al. 
1996)), in heart failure patients down-regulation alone is unlikely to be the correct 
explanation. Bernardi et al (Bernardi, Salvucci et al. 1990) "showed that with 
exercise, even in normal subjects the LF component could increase and then decrease 
remarkably towards peak exercise. These relatively sudden changes are unlikely to 
be due to saturation of the sinus node. 
Van de Borne et al (Van de Borne, Montano et al. 1997), using simultaneous 
recordings of resting-muscle sympathetic nerve activity (MSNA) and R-R interval in 
21 patients with chronic heart failure (CHF), have demonstrated a close coherence 
between variability patterns of the RR interval and MSNA. The LF variability of 
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MSNA was also absent in patients with severe heart failure, and this finding was 
closely coherent with the abnormal variability of RR interval. 
These results suggest a central autonomic regulatory impairment in heart 
failure-an impairment reflected in reduced LF components not only of the RR 
interval fluctuations but also in MSNA. The reason for this central defect is 
probably multifactoral including excessive circulating levels of catecholamines, 
angiotensin, or vasopressin, which may compromise autonomic related functions at a 
central level. 
Furthermore, arterial baroreceptor function is known to be impaired in heart 
failure and this may account for the depressed LF component if LF is merely 
reflecting baroreceptor function, as discussed earlier. This outcome may have 
important prognostic implications because impaired baroreceptor function has 
recently been confirmed as a marker of a much worse clinical outcome (Mortara, La 
Rovere et al. 1997), and therefore, indirectly, an absent LF component should also 
be. Indeed Mortara et al demonstrated a worse prognosis in heart failure patients 
with an absent LF component (Mortara, La Rovere et al. 1994). 
Since HRV reflects the function of the autonomic nervous system, it is of 
interest if the degree of depression of HRV in heart failure relates to other markers of 
neurohormonal activation such as levels of natriuretic peptides and cytokines. There 
is little data on this issue. 
An interesting issue is raised by the demonstration of decreased HRV in heart 
failure on one side and the relationship between cardiac related death and decreased 
HRV on the other. Decreased HRV is a powerfiil independent predictor of mortality 
and arrhythmic events following MI. It is also well known that heart failure patients 
represent a high-risk group for death. Up to 80% of heart failure patients die 
suddenly with an average 60% survival at 4 years. 
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3.2 Effect of Changes in Respiratory Frequency and Posture on 
Heart Rate Variability Analysis in Heart Failure 
Effect of changes in respiratory frequency and posture on HRV analysis in 
the time and frequency domain by power spectral analysis has been suggested to be a 
valid method of assessing sympatho-vagal balance, measured as the ratio of the 
power of the LF and the HF components (Malliani, Lombardi et al. 1994; Montano, 
Gnecchi-Ruscone et al. 1994). Saul et al. (Saul, Ami et al. 1988) found in patients 
with congestive heart failure that heart rate spectral power was reduced at all 
frequencies, especially LF, and others have confirmed that LF spectral power is 
paradoxically reduced or absent in severe heart failure (Mortara, La Rovere et al. 
1994). More recently, studies have used this technique for assessing the effects of 
drugs and other treatments in heart failure (Binkley, Haas et al. 1993; Binkley, 
Nunziata et al. 1994; Tuininga, van Veldhuisen et al. 1994; Butler, Naughton et al. 
1995). However, in normal subjects it is apparent that the LF and HF components 
are dependent on factors additional to sympathetic and parasympathetic activity such 
as baroreceptor function and respiration (Saul, Berger et al. 1989; Brown, Beightol et 
al. 1993; Laude, Goldman et al. 1993; Novak, Novak et al. 1993). Despite this, there 
is no published study to date if the effect of different breathing rates in the 
physiological range (10-20 breaths/min, 0.17Hz to 0.33Hz) on power spectral 
analysis of heart rate and SBP variability in patients with heart failure to determine if 
changes in respiratory rate have an important impact on measurement of the LF and 
HF components in this group of patients. 
Many studies of HRV use ambulatory ECG recordings (Holter monitoring) 
for both Time-Domain and Spectral analysis and little attention are paid to the effects 
of respiration or posture. These may be important especially in patients with heart 
failure, as symptomatic improvement is accompanied by a fall in respiratory rate and 
an increased proportion of the day spent in the upright position. 
3.3 Effect of Respiratory Rates on Baroreceptor Function in Heart Failure 
The protective role of a preserved arterial baroreflex in patients with CHF or 
with previous myocardial infarction is now well established (Mortara, La Rovere et 
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al. 1997; LaRovere, Bigger et al, 1998)，and in recent years much attention has been 
paid to drugs [e.g. scopolamine, pirenzepine, ACE inhibitors (Osterziel, Rohring et 
al. 1988; Casadei, Pipilis et al. 1993)] and interventions [e.g. physical exercise 
(Coats, Adamopoulos et al. 1992)] that are able to increase the vagal tone or the 
/ 
baroreflex sensitivity. A slow rate of breathing (in the range of 6 breaths/min) has 
several favorable effects on the cardiorespiratory system in patients with CHF: It 
increases resting oxygen saturation, has a beneficial effect upon ventilation/perfUsion 
(V/Q) mismatch, and improves exercise tolerance by reducing the sensation of 
dyspnea (Bemardi, Spadacini et al. 1998). It also reduces chemoreflex activation 
(Spicuzza, Gabutti et al. 2000) and muscle nerve sympathetic activity (Goso, Asanoi 
et al. 2001). Whether slow breathing has any effect on arterial baroreflex sensitivity 
in heart failure, however, was previously unknown until our study described in this 
thesis. 
3.4 Effect of Treatment on Heart Rate Variability in Heart Failure 
Patients 
Relatively few studies have been done assessing the effect of therapy on 
HRV indices in heart failure. Binkley et al (Binkley, Haas et al. 1993) demonstrated 
in 13 heart failure patients that treatment with an angiotensin converting enzyme 
inhibitor (zofenopril) was associated with a 50% increase in total HRV and a 
significant two-fold increase in the HF component suggesting significant 
augmentation of parasympathetic tone. 
Slatton et al (Slatton, Irani et al. 1997) studied the effect of digoxin in 19 
patients with moderate heart failure and a left ventricular ejection fraction < 0.45. 
The patients were restudied after 2 weeks of low dose (0.125 mg daily) and 2 weeks 
of moderate dose digoxin (0.25 mg daily). Autonomic function was studied by 
assessing HRV on 24 hr holter monitoring. They found that low dose digoxin 
reduced heart rate and increased heart rate variability. Moderate dose digoxin 
produced no additional increase in HRV or reduction in sympathetic activity as 
manifested by heart rate, plasma norepinephrine or the LF/HF ratio. Neither low nor 
moderate dose digoxin increased parasympathetic activity, a rather surprising result 
because it has always been assumed that digoxin increases vagal tone. 
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An interesting study by Casadei et al (Casadei, Conway et al. 1996) studied 
the effects of transdermal scopolamine on heart rate variability, baroreflex sensitivity 
and exercise performance in 16 patients with chronic, stable heart failure due to 
/ 
ischemic cardiomyopathy. Scopolamine, an antimuscarine agent is usually used for 
its anticholinergic action; but it will, like atropine, in low doses cause a paradoxical 
increase in cardiac vagal activity. This could increase electrical stability of the 
myocardium and reduce the risk of lethal arrhythmias. However, vagal stimulation 
exerts a negative inotropic effect on the heart (DeGeest, Levy et al. 1965). In the 
study, transdermal scopolamine (500 micrograms delivered over 72 hrs) or placebo 
patch was administered for 48 hrs. In both the healthy controls (8 age matched 
subjects) and heart failure patients scopolamine produced a reduction in 24 hr 
average heart rate and an increase in time domain measures of HRV. Baroreflex 
sensitivity evaluated by the phenylephrine technique increased significantly with 
scopolamine in the heart failure group and in healthy volunteers as did the amplitude 
of respiratory sounds in arrhythmia as assessed by auto regressive spectral analysis. 
There was no change in exercise performance but the heart rate at sudden maximum 
exercise was significantly reduced by scopolamine in each group. They concluded 
that in patients with a mild to moderate heart failure low dose of scopolamine 
increased tonic and reflex cardiac vagal activity. However, there was no effect on 
exercise tolerance or the incidence of severity of ventricular arrhythmias. 
• 
p-blockers are increasingly used for the treatment of heart failure and have 
been shown unequivocally to benefit left ventricular function, symptoms, quality of 
life as well as delay clinical progression, reduce mortality and improve the overall 
function of the heart. The -bl o ckers used were metoprolol in the MERIT-HF study 
(MERIT-HF. 1999)，carvedilol in the COPERNICUS trial (Packer, Coats et al. 2001) 
and bisoprolol in the CIBIS-II study (CIBIS-II 1999). 
However, there is little data on the impact of P-blocker therapy on autonomic 
and baroreceptor function in patients with heart failure. Moreover, these three P 
blockers differ remarkably in a variety of ways including receptor selectivity, lipid 
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solubility, the ability to cross the blood brain barrier and vasodilatation properties 
(Prichard 1992). 
Metoprolol is a lipophilic (31-receptor antagonist which crosses readily into 
the brain, increases vagal tone and appears to have a more favourable effect on 
sudden death and ventricular fibrillation than hydrophilic P-blockers (Ablad, Bjuro et 
al. 1991; Kendall, Lynch et al. 1995). 
In an earlier study Rahman et al found that metoprolol therapy reduced 
muscle sympathetic nerve activity and calf vascular resistance in 6 patients with 
dilated cardiomyopathy. However, in a single subject who received sotalol, burst 
frequency and calf resistance were higher despite similar hemodynamic 
improvement (Rahaman, Ham et al. 1995), suggesting a drug specific, perhaps 
central sympatho-inhibitory action of metoprolol. 
Carvedilol is an interesting drug as it provides non-selective P-adrenergic 
receptor antagonism ((3i and P2) but in addition has a ai adrenergic blocking action 
and a documented anti-oxidant activity. These additional actions of carvedilol may 
provide further clinical benefit for the patients with heart failure. Despite its proven 
effect in heart failure (Packer, Coats et al. 2001) to-date there has been little work on 
its action on the autonomic system. One recent study (Azevedo, Kubo et al. 2001) 
found that therapy with carvedilol in 17 patients with heart failure caused significant 
decreases in systemic and cardiac norepinephrine spillover, an indirect measure of 
norepinephrine release. Carvedilol had no effect on sympathetic efferent neuronal 
discharge to skeletal muscle. These results suggest that carvedilol causes its 
sympathoinhibitory effect by blocking peripheral prejunctional p-adrenergic 
receptors. 
Celiprolol was one of the first vasodilating P-blockers to be introduced. The 
vasodilating action of celiprolol is the result of various mechanisms. Celiprolol 
possesses some weak p2-receptor agonist activity (Prichard 1992). There is evidence 
that celiprolol in addition has a weak ai blocking activity and a direct smooth muscle 
relaxing effect as its relaxing effect on human arteries and veins is not completely 
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inhibited by P-blockade (Prichard 1992). Celiprolol has been widely used for the 
treatment of hypertension and angina and has been shown to have the equivalent 
antihypertensive efficacy to other P-blockers such as propranolol, atenolol, 
metoprolol and pindolol (Norris 1988; Dunn and Spencer 1995). The drug also has 
similar antihypertensive effect as an angiotensin converting enzyme inhibitor such as 
enalapril (Norris 1988). It induces a reduction of peripheral vascular resistance with 
maintenance of resting heart rate, cardiac output and renal perfusion. It also shows 
modest improvements in plasma lipid profiles (Dunn and Spencer 1995). 
We were interested to study potential differences between carvedilol, 
celiprolol and metoprolol in their action on autonomic dysfunction, especially 
baroreceptor function. 
In summary HRV reflects the activity of the autonomic nervous system and 
can be assessed by two main methods, time-domain and Spectral analysis. In 
addition spectral analysis of HRV can provide an index of baroreceptor function. 
HRV and baroreceptor function are known to be depressed in heart failure but the 
effects of posture, respiration and p-blockers have not been explored in detail and 
these are，therefore, the main purpose of this thesis. 
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4 AIMS 
The aim of this thesis was to assess the utility of HRV measurement and the 
/ 
importance of arterial baroreflex sensitivity in heart failure. Secondarily, I wanted to 
observe the influence of respiratory rate and drugs upon these variables. Therefore, 
the following studies were carried out: 
4.1 Effect of Changes in Respiratory Frequency and Posture on 
Heart Rate Variability 
We have assessed the effects of different paced breathing rates and posture on 
commonly used (LF, HF power and LF/HF ratio) measurements derived from 
spectral analysis of HRV and blood pressure variability in CHF patients and normal 
subjects. 
4.2 Effect of Slow Breathing 
To assess whether the arterial baroreflex can be enhanced by controlled slow 
respiration (6 breaths/min) in healthy subjects and in patients with CHF. This may 
have practical implications as this breathing pattern can easily be learned by patients 
with CHF (Bemardi, Spadacini et al. 1998). 
4.3 Effect of Therapeutic Interventions in Chronic Heart Failure 
4.3.1 A Comparison of Celiprolol with Metoprolol 
We carried out a randomized double blind trial of celiprolol versus 
metoprolol and placebo over a long-term (3 months) followed by an open phase of 
one year. In the main study we assessed the effect of these drugs on simple heart rate 
measured over 24 hours and in a sub-study the effects of the two drugs on autonomic 
and baroreceptor function was assessed using spectral analysis of heart rate 
variability. 
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4.3.2 A Comparison of Carvedilol with Metoprolol 
We carried out a randomized double-blind trial to compare carvedilol with 
metoprolol over a three-month period to determine whether P-adrenoreceptor 
/ 
blockade improved baroreceptor fiinction and vagal tone in chronic heart failure, and 
whether there were any differences between the effects of metoprolol and carvedilol. 
In all these studies patients with atrial fibrillation, sinus node dysfunction, or 
implanted pacemakers will be excluded from the study. The studies were approved 




/ 5.1 Impact of Changes in Respiratory Frequency and Posture on 
Power Spectral Analysis of Heart Rate and Systolic Blood 
Pressure Variability in Normal Subjects and Patients with 
Heart Failure 
There are special considerations when one undertakes recordings for spectral 
analysis in patients with heart failure. Even in normal subjects it is apparent that 
both the LF and HF components are dependent on factors additional to sympathetic 
and parasympathetic activity, such as baroreceptor function and respiration. In heart 
failure the problems are compounded by the presence of ectopic rhythms and the 
frequent absence of a LF component, as shown in Figure 6，page 45. Many studies 
in this area have used ambulatory ECG recordings, but little attention was paid to the 
effects of either respiration or posture in patients with heart failure. This may be 
important in the evaluation of heart failure, since improvement is often associated 
with a lower respiratory rate and more time standing upright. 
For this reason the first study I carried out was designed to assess the effects 
of posture and respiration on HRV indices in patients with heart failure. 
5.1.1 Subjects 
Eleven patients (9 male, 2 female), with clinically obvious but compensated 
congestive heart failure (NYHA fiinctional class II-IV) mean age 57 ± 15 years, with 
an ejection fraction of 35 + 8% measured by two-dimensional echocardiography or 
MUG A scans, and nine normal subjects (mean age 45 土 2 years, 6 male) without any 
evidence of cardiovascular disease (including hypertension, heart failure, or diabetes) 
and not taking any medication were studied. All heart failure patients were taking 
diuretics, frusemide and an ACE inhibitor. One patient was unable to remain supine 
during the whole recording period due to orthopnea and was supported a few degrees 
whilst the supine recordings were taken. 
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5.1.2 Recording Technique and Protocol 
The subjects were studied in a quiet, soundproof room initially supine and 
then after standing for 5 minutes. ECG, finger blood pressure (via 
photoplethysmographic transducer, Ohmeda Finapres), and respiration rate (via 
impedance pneumograph, which also gave semi-quantitative tidal volume estimates) 
were recorded onto computer continuously throughout the study period. Recordings 
were taken in 5-7 minute periods during spontaneous respiration and controlled 
breathing at rates of 10，15 and 20 breaths per minute (0.17 Hz, 0.25Hz and 0.33Hz 
respectively) both supine and standing. Controlled respiration was achieved by 
asking the subjects to inhale and exhale in synchrony with a recorded message from 
a cassette tape recorder. The cassette was replayed for each recording session. The 
tapes were prerecorded to maintain a respiratory rate at 10, 15 or 20 breaths/min. 
Subjects were trained in following the tape recorder before data were recorded for 
analysis. Depth of breathing or tidal volume was not controlled and subjects were 
allowed to breathe comfortably to avoid hyper- or hypoventilation. 
5.1.3 Signal Acquisition 
As previously used (Bemardi, Salvucci et al. 1990)，the data was digitized 
off-line by a 12-bit analogue-to-digital converter at a sampling rate of 500 samples 
per sec. The converter was connected to a Macintosh II computer. A 'C' language 
program identified all the QRS complexes in each sequence, and then located the 
peak of each R wave. From these data the R-R intervals were obtained. For each 
step of the protocol at least 256 R-R intervals were analyzed. The non-oscillatory 
(DC) component and slow trends were removed from each sequence by subtraction 
of that same sequence after 124 long-windows moving procedure, following an 
algorithm described previously (Press, Flannery et al. 1986). 
The respiratory signal obtained from the impedance pneumograph was 
expressed in arbitrary values (mV output from the device); only the signal occurring 
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at the peak of the R wave was measured. Systolic and diastolic blood pressures were 
similarly identified. Premature beats were interactively identified and corrected by 
linear interpolation of the previous and the following beats. All data was stored on 
computer diskettes for further analysis. 
/ 
5.1.4 Power Spectral Analysis 
Power spectral analysis was applied to respiratory, R-R interval and SBP 
signals, using an autoregressive model as described in the previous chapter. Spectral 
components were obtained by a decomposition method. The area below each 
spectral peak, mean variance and total power in the LF (0.04 to 0.15) and HF 
component (0.15 to 0.4Hz) was measured (Figure 5, page 44 & Figure 6，page 45). 
The respiratory component of the HF band could be readily identified by 
comparison with the respiratory power spectrum. In this way it was possible to be 
certain that the HF component at lower breathing rates did not encroach into the 
preset LF band. In addition, in some recordings a component below 0.04Hz (VLF) 
was apparent which contributed significantly to total power. The VLF, LF and HF 
components are presented in absolute units (ms�）and LF and HF as a percentage of 
total power (%tot), and as normalized units (nu) after subtraction of VLF as 
previously described (Pagani, Lombardi et al. 1986; Montano, Gnecchi-Ruscone et 
al. 1994). 
All ectopic beats during the recording were removed and replaced by linear 
interpolation. Recordings with less than 256 beats were not analyzed. Power 
I 
spectral analysis was not performed on patients whose ectopic beats comprised more 
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Figure 5 Typical example of spectral recordings from a normal subject 
Note the increase in LF power on standing. 
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Figure 6 Typical example of spectral recording from a patient with heart 
failure 
Note the absent/reduced LF component with no change on standing and the effect of 
respiration, which increases HF power at lower respiration rates. 
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5.1.5 Statistical Analysis 
Unless otherwise indicated, data are expressed as mean 土 SEM. Since 
Gaussian distribution was uncertain, non-parametric tests (Wilcoxon signed-rank test 
for paired data, Mann-Whitney U-test for non-paired data and Friedman non-
parametric repeated measures test) were used to evaluate statistical significance of 
effects of different breathing rates and posture within and between groups. A value 
of p less than 0.05 was considered significant. 
5.1.6 Results 
(Table 4, page 49) & (Table 5, page 50); (Figure 7, page 51 & Figure 8, page 52) 
Spontaneous Respiration Supine 
The mean respiratory frequency during spontaneous respiration while supine 
was 0.25 土 0.02 Hz in normal subjects and 0.27 土 0.02 Hz in patients with CHF. 
The LF component of RR spectra expressed either as % total or as nu was low in the 
CHF group, and six of these patients had an undetectable LF component. A similar 
pattern was noted for SBP variability, with reduced LF component, a relatively stable 
HF component and reduced LF/HF ratio compared to normal values (p=0.03). 
Spontaneous Respiration Standing 
On standing, the mean spontaneous respiratory frequency was 0.28 士 0.03 Hz 
in normal subjects and 0.29 士 0.02 Hz in patients with CHF. In normal subjects, R-R 
variance decreased on standing compared with supine values, and this was associated 
with a significant increase in LF component (p=0.04), a fall in HF component and a 
significant increase in LF/HF ratio (p=0.003). No significant change was seen in the 
heart failure group for R-R LF and HF components, and R-R LF/HF ratio was 
unchanged compared with supine values. Thus the different effect of standing on the 
LF/HF ratio in normal subject and patients with CHF was also highly significant 
(p=0.003). In the SBP spectra with spontaneous respiration, the heart failure group 
upon standing showed a non-significant increase in the LF component, a fall in HF 
component but a significant increase in the LF:HF ratio (p=0.03). In normal subjects 
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the LF component of SBP variability increased significantly on standing [37 土 12 to 
60 士 13 (o/o tot); p = 0.03], as did the LF/HF ratio (p=0.03). 
Thus, in patients with CHF, posture was associated with no change in LF, 
HF or LF/HF ratio in the R-R spectra, while in the SBP spectra LF/HF did increase. 
Therefore, the response of heart rate and blood pressure variability to changes in 
posture differ, and it appears that, unlike heart rate, SBP can still be modulated by 
autonomic tone. 
Controlled breathing, supine 
For patients with CHF, slowing breathing rates in the R-R spectra from 20 to 
10 breaths/min (0.33Hz to 0.17Hz) produced a significant increase in HF, whether 
expressed in absolute units (p=0.005) or as %tot (p=0.03). HF (nu) of R-R 
variability showed a similar pattern, although the changes were not quite significant 
(p=0.06). 
R-R variance was similar at breathing rates of 20 and 15 breaths/min. but 
increased significantly at a breathing rate of 10 breaths/min (p=0.04, compared with 
20 breaths/min). A similar pattern was seen with HF and LF components: 
differences between respiratory rates of 15 and 20 breaths /min were small, with the 
major change occurring at a breathing rate of 10 breaths /min. 
In the SBP spectra, LF power fell (not significant) but HF power (% tol) 
increased significantly (p=0.02) and there was a significant reduction in SBP LF/HF 
ratio with slower breathing frequencies (p=0.02). 
For the normal subjects the effects of respiration on R-R spectra were similar, 
with an increase in R-R variance with lower respiratory frequency (p=0.02) and a 
significant (p=0.004) increase in HF (absolute units), although this was not 
significant when expressed as % tot or nu. LF/HF ratio fell with lower breathing 
frequencies but this was not significant (p=0.97). In the SBP spectra (normal 
subjects), LF and HF changes with different breathing rates were not significant. 
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Thus, surprisingly, the effects of different respiratory rates on supine SBP 
LF/HF ratio appear to be greater in patients with CHF than in normal subjects. 
Controlled breathing, standing 
/ 
In the heart failure group, on standing, smaller but comparable changes in LF 
and HF components of R-R spectra were seen during paced breathing, with a 
decrease in LF and a small increase in HF at lower breathing rates and a fall in 
LF/HF ratio (p=0.05). More significant changes were seen in the SBP spectra, with 
a significant fall in LF/HF ratio at lower respiratory frequency (p=0.03). 
In normal subjects the changes in R-R spectra with paced breathing were 
more obvious on standing, with a significant reduction in LF (nu) and a significant 
increase in HF (p=0.004; absolute units) with lower breathing rates, and a 
corresponding fall in LF/HF ratio (p=0.01). Similar changes were seen in the SBP 
spectra of normal subjects, with a fall in LF and an increase of HF components, and a 
significant fall in LF/HF ratio with reduced paced breathing rates (p=0.01). 
In both patients with heart failure and normal subjects the LF component with 
controlled breathing was higher on standing compared with supine, although this was 
statistically significant only in the normal subjects (p<0.05, supine compare with 
standing at 10, 15 and 20 breaths/min). Thus, in contrast to the supine position, 
standing effected much greater changes in normal subjects than in patients with heart 
failure. 
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Table 4 Heart Rate (R-R) Variability 
R-R mean RR 
(ms) variance VLF(ms^) LF(ms^) HF(ms^) LF(nu) HF(nu) LF/HF  (ms^   
Heart Failure  
1. Supine : 
Respiration 768 ±41.6 582 ± 158 47.1 ±26 60.4 士 27 191.7 土 76 12.5 土 5.4 63.7 士 5.4 0.3 土 0.1 
Controlled -
10/min. 782 ±41.3 747 土 283^ 49.1 ±39 19.9 ± 10.2 522.8 土 228g 10.7 士 5.2 74.0 ±7.7 0.3 ±0.2 
15/min. 770±4"1? 454 ± 11.6 士 ^ 72.5 ± 3 5 T " 271.3 ± 150 19.2±5.0 58.5 
20/min. 788 ±45.0 461 土 164d 79.3 土 63 58.9 士 28.5 214.2 土 108g 16.4 ±3.6 64.0 ±5.0 0.3 土 0.1 
2. Standing 
^pont 741 ±33.1 694 土 291 389.7 ±266 10.6 士 5.7 121 土 46 8.1 士 4.7 64.3 ± 8.0 0.3 ±0.2 Respiration  
Controlled -
10/min. 731 ±34.3 836 士 307 0.0 ±0.0 42.3 士 18.7 265.5 ± 88 15.0 ±7.1 66.1 ±6.4 0.3 ± 0 . 2 �  
15/min. 728 土 455 ± 13.8 士厂 57.8 ± 175.1 ±84 21.0 ±6.2 52.0 ±T7" 0.5 ±0.2 
20/min. 725 ±33.2 397 土 13id 9.3 士 9.3 42.2 土 20 109.3 ±44 25.6 ±9.3 54.1 ±7.7 1.0 ± 0 . 5 �  
Normals  
1. Supine  
R ^ p L t i o n 805± 17.3 1083 ±412 0.0 士 0.0 171.7 ± 113a 279.1 土 108 a 25.6 士 59.8 土 0.6±0.2b 
Controlled -
10/min. 830 ±31.2 2545 士 1513e 63.7 士 42 733 士 557 1407±783g 15.6 ±6.4 79.4 ±6.3 0.3 士 0.1  
15/min. 7 8 2 ± 2 " i J 8 5 5 士 s S T " 12.8 士 l I F 175.7 ± l i l ? 3 4 5 . 8 土 121 22.7 ± 5.2 68.0 士TT" 0.4 ± 0 . 1  
20/min. 821 ±30.0 872 ±184^ 44.8 ±44.8 61.4 土 21.3 304.2 士 112 g 21.2 ±7.4 70.9 士 7.1 0.4 土 0.2 
2. Standing  
S s p L t i o n 728 士 27.4 854 士 129 100 ± 100 286.3 士 93.3 士 62 a 59.3 ± 22.7 ± 9.6a 0.3 ± 4.7b 
Controlled -
10/min. 708 土 21.1 965 土 204 69.4 土 69.4 294.8 ± 140.8 429.5 土 108^ 33.4 土 8.8 63.8 ± 8.5 0.8 士 0.3 
15/min. 6 9 6 ± i 5 ^ 742 ± 68.9 土 93.4 ± 187.3 ± 109 37.3±9.1 51.2土TT 1.3±0.5 
20/min. 692 ±20.2 720 ±96.3 0.0 土 0.0 231.9 ±66.7 89.6 士 40^ 65.9 士 7.1 25.3 ±4.8 4 . 3 ± 1 / 
Data are expressed as mean 士 SEM. (nu)=nomialized units (minus VLF power). 
Symbols refer to statistical significance between (1) changes between supine and 
standing: ^ p<0.05; ^p<0.005; and (2) change with different respiratory rates:� 
p<0.05; d p<0.04; e p<0.02; f pO.Ol; ^ p<0.005 
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Table 5 Systolic Blood Pressure (SBP) Variability 
SBP mean „ „ 
(mmHg) ( ^ H g " ) VLF LF(ms^) HF(ms') LF(nu) HF(nu) LF/HF 
Heart Failure  
1. Supine , 
Respiration 121 ±7.1 33.9 ±9.0 7.3 ±4.9 3.3 士 2.3 5.5 ± 1.7 20.3 士 8.3 53.3 ±9.2 1.0 土 0.5 a 
Controlled -
10/min. 127 土 9.0 26.3 ±5.1 3.2 士 1.8 0.6 士 0.4 11 士 3.3 9.8 ± 5.7 68.1 土 8.0 0.2 ±0.1*" 
15/min. ~ ± 7 . 8 " l i o 士 7.8 " 7 7 + 3 . 9 2.1 ± ~ 8 士 2 . 5 _ 19.4 ±6.5一 60.2 土 一 0.6 ±0.3 
20/min. 128 士 7.8 26.1 ±5.7 9.0 土 2.9 2.1 ± 1.1 5.3 士 1.5 22.2 ±7.3 60.7 士 8.5 0.8±0.4&_ 
2. Standing  
【二ration 131 土 10.0 34.8 士 5.8 12.1 士 4.5 10.4 土 4.6 5.1 ±2.3 35.4 士 11.8 29.1 ±8.3 3.2 士 1.3 a 
Controlled -
10/min. 119 ±8.6 49.5 土 11.1 10 土 5.5 4.4 土 4.1 16 ±4.4 11.7 ±6.8 55.0 土 10.2 0.4 士 0.3 e 
15/min. 119.4 土 10.0 37.0±8.5 17 ± 11.6 一 6.0 ±2.5 9 .2±2.4 ~^8.1±5.7 一44.0±5.2 1).7士0.2 
20/min. 122 土 10.1 5 7 . 0 ±22.3 5.6 ± 3 . 3 6.0 ± 2 . 7 7.7 土 2.5 2 4 . 1 土 8.4 土 8.1 & ± 0 . 4 。 
Normals  
1. Supine  
Respiration 116 土 3.6 31.4 ±7.1 17.3 土 9 1.2 ±0.4 2.0 ± 1 46.3 土 13.0 40.7 土 10.3 6.2 ± 4.1 & 
Controlled -
10/min. 123 ±6.8 33.3 土 3.7 12.3 ±5.5 3.1 ± 1.1 9 ±2.8 27.2 土 9.6 56.4 土 11.6 1.6 土 1.1 
15/min. 120 ±4."^ 27.0 ± 3.6 ± 2.4 _ 2.5 士 0.5 3.8 ±0.9 37.2 ± 8.3 _ 4 9 . 0 土 7.8 1.1 ±0.4 
20/min. 1"16 士 5.6 士 19.1 5.8 ±3.9 1.7 3 士 0.4— 30.4 士 8.2_ 65.3 ± 7 i ~ 0.7 ± 0.2 _ 
2. Standing - - - — • - — 
RespLtion 120 土 7.1 41.8 土 8.5 1.3±1.3 15.7 土 6 3.2 土 1.4 60.5 ± 12.6 33.5±11.2 11.3 士 4.8a 
Controlled -
10/min. 115±5.4 48.1 ±8.6 6.4 士 6.4 17.4±7.0 15.1 ± 3.7 43.8 ± 10.2 e 53.1 ± 10.1 b 1.5 ± 0.5 & 
15/min. 115±5.9 36.2 土 3.6 5.3±3.5 11.4士U 7.3 ± 46.9 ± 11.厂 41.7 ± 10.1~ 3.2 ± 1.6 
20/min. 114 士 5.4 44.8 土 4.8 0.0 士 0.0 18.5 ±5.4 5.2 ± 1.2 68.0 土 7.0 e 28.9 土 7.0 b 6.2 土 2.4 b 
Data are expressed as mean 土 SEM. (nu)=normalized units (minus VLF power). 
Symbols refer to statistical significance of: (1) changes between supine and 
standing: ^ p<0.03, and (2) changes with different respiratory rates: ^ p<0.01,� 
p<0.03 
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Figure 7 Effect of different respiratory rates on LF and HF components (% 
total) of heart rate variability (R-R) recorded supine and standing in patients 
with heart failure and normal subjects 
51 
Normals-supine Heart Failure-supine 
75-1 75-, 
二 ^ T SBP-LF 
S T S -r MiSBP-HF r 50- T T 工 •• SBP-LF e 50- •• 丄 *p=0.02 I •• T — • —SBP-HF I • • 
i : i _ i l l I I i l l 量:y J _ i 
Spontan. 10 15 20 Spontan. 10 15 20 
Respiratory rate (breaths/min) Respiratory rate (breaths/min) 
Normals-standing Heart Failure-Standing 
100-1 75-1 
^ , "S 
•rf W 知 
r 75- T rL tmu SBP-LP • 50- 丄 CSU SBP-LF 
I [ik * * T _ S B P - H F I T • T T HBSBP-HF 
I i l i J i 棚 1 1 i J i l i l 
Spontan. 10 15 20 Spontan. 10 15 20 
Respiratory rate (breaths/min) Respiratory rate (breaths/min) 
Figure 8 Effect of different respiratory rates on LF and HF components (% 
total) of SBP variability recorded supine and standing in patients with heart 
failure and normal subjects 
5.1.7 Discussion 
Many clinical studies have used Holter systems for assessing HRV in the 
frequency domain, but usually no allowance is made for the effects of respiration or 
posture. In a review of published studies, Brown et al (Brown, Beightol et al. 1993) 
found that in nearly 50% of studies the respiratory rate was not controlled during the 
study period. 
Although the effect of different respiratory rates have been studied before in 
normal subjects (Saul, Berger et al. 1989; Brown, Beightol et al. 1993; Laude, 
Goldman et al. 1993; Novak, Novak et al. 1993)，this study has shown for the first 
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time that this effect of respiration is also seen in patients with heart failure, despite 
the general reduction in heart rate and blood pressure spectral power which is 
apparent at all frequencies but especially in the LF band. 
/ 
In addition, the important effect of respiration on the spectral components of 
heart rate and SBP variability in normal subject is confirmed (Saul, Berger et al. 
1989; Brown, Beightol et al. 1993; Laude, Goldman et al. 1993; Novak, Novak et al. 
1993). HF power (expressed in absolute units) increased significantly with lower 
respiratory rates. 
The mechanism of respiratory sinus arrhythmia is not entirely clear (Malliani, 
Lombardi et al. 1994). The traditional explanation is that the waxing and waning of 
the pulse rate is caused by a central “oscillator” entrained to the respiratory rate as a 
result of the afferent input from broncho-pulmonary receptors. However it is clear 
that other non-neural mechanical mechanisms are involved as inspiration increases 
heart rate in the denervated transplanted heart (Bemardi, Salvucci et al. 1990). The 
role of the baroreceptors in the production of respiratory sinus arrhythmia is 
emphasized in the model proposed by De Boer et al (De Boer, Karemarker et al. 
1987), and may explain the different response to respiration rate changes between 
normal subjects and patients with heart failure. These studies emphasize the 
importance of respiration in cardiovascular control, the need to measure respiration 
and to examine for coherence with the respiratory signal, particularly if power 
spectral analysis of HRV is used to assess the effect of drugs or other therapies on 
sympatho-vagal balance in CHF. 
Postural effects on R-R power spectra were as expected. In normal subjects 
there was the expected rise in LF and reduction in HF components, as reported 
previously (Montano, Gnecchi-Ruscone et al. 1994; Piccirillo, Fimognari et al. 
1995). Postural changes had less effect on R-R LF and HF in the heart failure group 
probably because of the blunted cardiovascular reflex responses (Eckberg and 
Sleight 1992; Saul 1992), but interestingly, the effects of both posture and respiratory 
frequency changes appeared to be more obvious on SBP than R-R LF and HF 
components, possibly indicating a differential effect on cardiac and vascular 
modulation. 
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This study has also confirmed the paradoxical reduction in the LF component 
of RR and to a lesser extent of SBP spectra variability in patients with heart failure 
(Saul, Ami et al, 1988; Saul 1992; Mortara, La Rovere et al. 1994). Although the 
/ 
degree of the reduction in the LF component is related to the severity of the disease 
(Guzzetti, Cogliati et al. 1995), studies have suggested that the LF component is not 
a measure of sympathetic activity per se (Malik and Camm 1993; Ahmed, Kadish et 
al. 1994; Kingwell, Thompson et al. 1994)，although the ratio of LF/HF ratio of HRV 
(but not SBP) is a crude measure of sympatho-vagal balance (Malliani, Lombardi et 
al. 1994; Montano，Gnecchi-Ruscone et al. 1994). 
The mechanism for the reduced or absent LF component in RR spectra of 
patients with heart failure is not entirely clear. Some have suggested that this is due 
to supersaturation of end organ receptors by excessive and prolonged sympathetic 
stimulation and decreased responsiveness of the sinus node to neural modulatory 
influences (Kingwell, Thompson et al. 1994; Mortara, La Rovere et al. 1994; 
Guzzetti, Cogliati et al. 1995). 
It has been suggested that the LF component reflects the baroreflexes and is 
due to the phase lag in the baroreceptor loop (Bemardi, Leuzzi et al. 1994), 
generated because the vagally mediated response (mainly cardiac) is fast while the 
sympathetic response (largely vascular) is slower (De Boer, Karemarker et al. 1987). 
The system will oscillate at about O.lHz，the same frequency as the LF component. 
In another study, Ahmed et al (Ahmed, Kadish et al. 1994) showed in normal 
subjects that although tilting to an upright position slightly increased LF power and 
LF/HF ratio, these changes were not produced by other forms of P-adrenergic 
stimulation, such as adrenaline and isoprenaline infusion, which caused no 
significant change in LF or HF power, although this constant p-adrenergic 
stimulation does not mimic the normal phasic oscillations in sympathetic nerve 
activity. Paradoxically, exercise produced a reduction in both HF and LF power. 
Similarly, Bemardi et al (Bemardi, Salvucci et al. 1990) found in normal 
subjects that when approaching peak exercise the relative proportion of LF decreased 
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and HF proportionally increased. These changes clearly cannot be due to decreased 
adrenergic sensitivity but are more likely to be due to a change in baroreceptor gain. 
In our study, LF component of the SBP spectra in patients with CHF 
/ 
appeared to be better preserved (although still subnormal) than in the R-R spectra, 
and there was even a small (non significant) rise upon standing. This indicates that 
the sinus node and vascular system differ in their responsiveness to neural 
modulation in CHF, but it is not possible to determine in this study if this relates to 
reduced baroreceptor gain or differing end-organ sensitivities. Baroreceptor gain is 
known to be reduced in heart failure and there are many possible reasons for this 
(Eckberg and Sleight 1992; Ferguson and Mark 1994). 
Tidal volume was not controlled in this study so that the individuals could 
breathe at a comfortable rate without hyperventilation or significant changes in acid-
base balance which might influence the results. Although there must have been 
minor changes in tidal volume at different respiratory frequencies, Bemardi et al. 
found that changes in tidal volume are far less important than breathing frequency 
(Bemardi, Keller et al. 1989). 
During spontaneous breathing there were much wider variations in tidal 
volume and often the breathing rate changed significantly which gave a broader HF 
band. However, the respiratory component of the R-R and SBP spectra could be 
identified by comparison with the respiratory spectral analysis recording, 
emphasizing the importance of recording the respiratory rate during spontaneous 
breathing in order for the respiratory HF band is accurately identified. It is possible 
that mental concentration required to follow the breathing instructions could induce a 
small alerting or stress reaction which might increase sympathetic outflow. 
Another potential source of error is the presence of ectopic heartbeats, which 
were more frequent in the heart failure group than normal subjects. These were 
removed from the tachogram by linear interpolation. However this would tend to 
increase the power in the LF band without affecting the HF power appreciably 
(Myers, Workman et al. 1993). The mean age of the normal subjects was lower than 
the patients with CHF (45 士 2 years compare with 57 ± 15 years), but according to 
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the study by Piccirillo et al. (Piccirillo, Fimognari et al. 1995), within the age group 
44-64 years there was little effect of age upon power spectral analysis of HRV 
(although the youngest group did have higher HF power than those over 64 years of 
age). The age difference is therefore unlikely to be important in this study. 
/ 
5.1.8 Summary 
In conclusion, this study has demonstrated that both respiratory frequency and 
posture have an important effect on measurements derived from power spectral 
analysis of heart rate and SBP variability in patients with CHF and normal subjects. 
Studies which utilize this technique should either control for respiration and posture 
during the period of measurement or identify respiratory rate if comparative studies 
on different occasions are carried out. 
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5.2 Slow Breathing Increases Arterial Baroreflex Sensitivity in 
Patients with Chronic Heart Failure 
As explained earlier spectral analysis of HRV can be used to assess 
baroreceptor function using the a-angle method. Our previous study suggested that a 
slower rate of breathing might have beneficial effects on vagal tone by increasing HF 
power. However, the effect of a slow breathing rate on baroreceptor function 
assessed by HRV had not been explored. With Dr Benardi from Pavia, Italy we 
participated in collaborative study to assess the impact of a slow breathing rate on 
baroreceptor function assessed using HRV measurements. A slow rate of breathing 
has several favourable effects on the cardiorespiratory system in patients with heart 
failure: it increases resting oxygen saturation, improves ventilation/perfusion 
mismatching, and improves exercise tolerance by reducing the sensation of 
dyspnoea; it also reduces chemoreflex activation and muscle sympathetic activity 
(Goso, Asanoi et al. 2001). Whether slow breathing has any effect on arterial 
baroreflex sensitivity in heart failure, however, is still unknown. 
5.2.1 Subjects 
We studied 81 patients with stable CHF (no changes in their signs and 
symptoms within the 2 weeks before examination) and 21 healthy controls. 
Exclusion criteria were the presence of atrial fibrillation, pulmonary disease, or a 
smoking history in the previous 2 years. Recordings of ECG, respiration 
(Respitrace), and blood pressure (Pilot model, Colin Tonometry) were obtained 
during 5 minutes of spontaneous breathing, 4 minutes of controlled breathing at 15 
breaths/min (i.e., similar to the spontaneous breathing rate; for the purpose of 
verifying to verify the effect of simple regularization of breathing rate), and 4 
minutes of controlled breathing at 6 breaths/min. 
5.2.2 Assessment of Baroreflex Sensitivity 
Assessment of baroreflex sensitivity was as previously described using the a-
angle method. Briefly, the gain of the arterial baroreflex was obtained by dividing 
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the amount of fluctuation in the RR interval by the fluctuation of SBP at the same 
frequency (respiration-synchronous and slow, nonrespiratory oscillations during 
spontaneous and controlled breathing at 15 breaths/min; 6 breaths/min unique 
oscillatory component during slow breathing). A mathematical function (squared 
/ 
coherence) was used to prove that fluctuations in the RR interval are in fact related to 
similar fluctuations in blood pressure. An example is shown in Figure 9，page 58. 
BOO I  
70OIM i  
0 t (min) 5’ 
1201 
IOOq t (min) 5, 
Cross Spectrum 
° 0 Hz 0.65 
Figure 9 Example of cross-spectral data from a patient with heart failure 
recorded during controlled respiration 
Coherences are drawn by thick lines and refer to the scale on the left side of the 
graph (values from 0 to 1); phase shifts are indicated by the thin lines and are 
expressed in radians (土 7c). High coherence is seen in the HF band (at the respiratory 
frequency 0.25 Hz) with a negative phase shift indicating that SBP precedes R-R. 
5.2.3 Statistical Analysis 
Comparison of variables at different breathing rates and in the 2 groups was 
done by analysis of variance for mixed design (factorial model for differences 
between groups, repeated measures for differences between breathing rates); 
comparisons between different NYHA classes were made by a factorial design 
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analysis of variance. If overall significance (P<0.05) was observed, then Sheffe's 
test was used to assess differences between different breathing patterns or between 
different NYHA classes. 
/ 
5.2.4 Results 
Clinical data for CHF patients and controls are shown in the Table 6, page 59. 
Table 6 Characteristics of the Subjects 
Patients 
with CHF Control P* 
"n ^ 
Age, y 58 土 1 55 ± 2 NS 
Weight, kg 75 ± 2 68 ± 3 NS 
Height, cm 170 ± 1 169 ± 2 NS 
Body mass index, k g W 25.7 土 0. 4 23.2 土 0. 8 < 0.01 
NYHA class 
I 6 ... 
II 33 ... 
III 27 ... 
IV 15 ... 
Etiology 
Coronary artery disease 40 ... 
Dilated cardiomyopathy 25 ... 
Valvular disease 3 ... 
Hypertensive 3 ... 
Idopathic 3 ... 
Other causes 7 ... 
Echocardiography 
evaluation 
Fractional shortening, % 23.5 土 1.3 ... 
Current Therapy 
ACE inhibitors 62 ... 
Digitalis 41 ... 
Diuretics 57 ... 
Nitrates 46 ... 
p - Blockers 32 ... 
Calcium antagonists 7 ... 
Amiodarone 30 ... 
Angiotensin II inhibitors 14 
Values are mean士SEM or number. 
•Differences between CHF and controls by unpaired t test. 
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During spontaneous breathing (breathing rates were 16.2士0.5 and 13.5±1.1 
breaths/min in CHF patients and controls, respectively [P=0.021])，HRV and 
/ 
baroreflex sensitivity were depressed in CHF patients compared with the controls 
(the SD of R-R intervals was 23.5±2.3 versus 41.9士2.8 ms, respectively, jP=0.0002). 
Breathing at 6 breaths/min, compared with spontaneous breathing, slightly 
increased overall spontaneous fluctuations in RR interval, reduced fluctuations in 
blood pressure, and significantly increased the baroreflex sensitivity in both CHF 
patients (from 5.0士0.3 to 6.1 士0.5 ms/mm Hg，户<0.0025) and controls (from 9.4士0.7 
to 13.8±1.0 ms/mm Hg,尸<0.0025) (Figure 10，page 61). 
Subjects with milder CHF tended to have greater baroreflex sensitivity. The 
overall inter-group differences, however, were not significant (baroreflex sensitivity 
during spontaneous breathing: NYHA class I, 6.8士 1.4; II，5.2士0.5; III，5.0±0.7; and 
IV, 3.9±0.5 ms/mm Hg; during breathing at 6 breaths/min: NYHA class I，9.3±1.9; 
II，6.0士0.6; III，6.2士0.9; and IV, 4.8士 1.2 ms/mm Hg). 
The increase in baroreflex sensitivity in CHF patients during breathing at 6 
breaths/min remained lower compared with the increase observed in controls, and it 
correlated positively with the value obtained during spontaneous breathing 
(r=+0.202, P=0.047). The effect of controlling the breathing rate at a frequency 
similar to that of spontaneous breathing (15breaths/min) did not induce significant 
changes in baroreflex sensitivity (Figure 10，page 61). 
The slow breathing rate in the CHF group also produced an increase in mean 
RR interval of 20 ms and a decrease in both systolic and diastolic blood pressure 
(systolic, from 117士3 to 110±4 mm Hg, P=0.009; diastolic, from 62士 1 to 59士 1 mm 
Hg, P=0.02) (Figure 11, page 61). No changes were observed during controlled 
breathing at 15 breaths/min compared with spontaneous breathing. 
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Figure 10 Effect of breathing rate on baroreflex sensitivity. 
*P<0.0001 vs controls; t^<0.0025 vs spontaneous breathing; 
§P<0.025 vs 15 breaths/min; J尸<0.0005 vs 15 breaths/min. 
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Figure 11 Effect of breathing rate on RR interval and blood pressure. 
*P<0.05 and **P<0.01 vs spontaneous breathing. 
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5.2.5 Discussion 
This study showed that slow breathing, both in healthy individuals and in the 
presence of CHF, can enhance baroreflex sensitivity significantly. This seems to 
occur through a relative increase in vagal activity and a reduction in sympathetic 
activity, as could be argued by the small reduction in heart rate observed during slow 
breathing and in the reduction in both systolic and diastolic blood pressures. 
The increase in tidal volume, which compensates for the reduced breathing 
rate in order to maintain minute ventilation (Bemardi, Spadacini et al. 1998; Goso, 
Asanoi et al. 2001)，could be responsible for these autonomic changes through a 
reduction in sympathetic activity (Goso, Asanoi et al. 2001) or via the Hering-Breuer 
reflex. 
In fact, sympathetic activity was found to increase with faster breathing rates 
and to decrease with higher tidal volumes in CHF (Naughton, Floras et al. 1998; 
Goso, Asanoi et al. 2001). The increase in baroreflex sensitivity depended on the 
slow breathing rate and not on the regularization obtained by controlling the 
breathing, in as much as this effect was not evident when breathing was controlled at 
a frequency (15 breaths/min) similar to the spontaneous rate. The reduction in blood 
pressures observed during slower and deeper respiration (Figure 11，page 61) 
confirms that this finding is the consequence of a reduced afterload，perhaps 
secondary to reduced sympathetic activity, (Goso, Asanoi et al. 2001) rather than a 
worsening of pump function. 
This more favorable sympatho-vagal balance also may be linked to a 
reduction of chemoreflex overactivity due to the reciprocal influences of these 2 
reflexes (Ponikowski, Chua et al. 1997). Additionally, the chemoreflex is reduced by 
the slow breathing, (Spicuzza, Gabutti et al. 2000)，producing another favorable 
effect on CHF. 
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In accordance with previous reports, the baroreflex sensitivity in patients with 
CHF in baseline was lower than that of controls, and the extent of the increase 
observed during slow breathing was smaller in the patients with CHF than in the 
controls. Interestingly, subjects with lower values at baseline tend to have smaller 
/ 
changes, whereas those with higher values show proportionally greater changes (as 
evidenced by the correlation between resting values and the increase induced by slow 
breathing). This is probably connected to the fact that reflex sensitivity shows a 
slightly skewed distribution, but it indicates that even a small increase with respect to 
a low initial value is clinically important (Ponikowski, Chua et al. 1997). 
Note that this improvement in baroreflex sensitivity was obtained by simply 
modifying the breathing pattern without administration of any drug; yet the extent of 
the increase in baroreflex sensitivity that we observed was similar to that obtained 
with captopril in patients with CHF (Osterziel, Rohring et al. 1988). 
It remains to be assessed whether these changes persist after resuming normal 
respiration. However, the slow breathing pattern is well tolerated by the patients; 
carbon dioxide is maintained within resting values, and chemoreflex activity is not 
stimulated by this breathing rate (Spicuzza, Gabutti et al. 2000). 
As this method does not stimulate ventilation, which may be deleterious in 
subjects who already have a tendency to hyperventilate, this pattern could be 
maintained as spontaneous and could be learned by appropriate training (Bemardi, 
Spadacini et al. 1998). Slow breathing has been found to improve resting oxygen 
saturation, and, possibly because of an enhanced mobilization of respiratory muscles 
and diaphragm, it may improve exercise capacity through a delayed onset of dyspnea 
and fatigue (Bemardi, Spadacini et al. 1998). 
5.2.6 Summary 
In this study we have described a novel, simple, and inexpensive method to 
increase the baroreflex sensitivity and vagal activity in patients with heart failure, 
which also increases oxygen saturation, improves ventilation efficiency and exercise 
tolerance [as previously described (Bemardi, Spadacini et al. 1998)], and reduces 
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sympathetic overactivity (Goso, Asanoi et al. 2001). Practicing slow and deep 
breathing may be beneficial in heart failure or in other diseases (e.g., coronary 
disease) in which impaired baroreflex sensitivity may have adverse prognostic value. 
/ 
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5.3 P-Blockers in Heart Failure: a Comparison of a Vasodilating P-
Blocker with Metoprolol on Heart Rate Variability by 24 Hour 
ECG Recordings (Time-Domain & Spectral Analysis) 
/ 
As stated earlier the beneficial effect of (3-blockers in the treatment of 
patients with congestive heart failure has now been demonstrated (Section 3.4, page 
35). However, at the time of planning the following study this was not entirely clear. 
Furthermore, there was no direct comparison of different p-blockers. In this study 
the clinical effects of metoprolol were compared to celiprolol, a vasodilating 
selective p-blocker. We also assessed the action of both drugs on HRV measured 
using 24 hour Holter analysis of time-domain and spectral indices. 
5.3.1 Trial Design 
This was a randomized, placebo-controlled, double-blind trial. After 
baseline measurements, patients were- randomized to receive treatment with 
celiprolol, metoprolol or placebo (in a ratio 2:2:1). All were in identical capsules. 
There was a four-week dose titration period, increasing the dose of celiprolol from 
25 mg daily to 200 mg, and of metoprolol from 6.25 mg twice daily to 50 mg twice 
daily, with a dosage increase at weekly intervals. A maintenance phase followed for 
eight weeks (total 12 weeks of treatment). At the end of 12 weeks, measurements 
were repeated. 
Clinical assessment, measurement of autonomic function (HRV), blood tests, 
and estimation of natriuretic peptides were carried out at four and eight weeks. 
Compliance to the medication regimen was verified by counting remaining 
medication at each visit. 
5.3.2 Study Patients 
We recruited 50 Chinese patients with a clinical diagnosis of CHF on 
standard therapy (diuretics, ACE inhibitors and digoxin) and LV ejection fraction < 
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45% (by radionuclide ventriculography or two-dimensional echocardiography) were 
recruited. Four patients had permanent pacemakers. 
Exclusion criteria for this study were: 
• valvular heart disease, 
• active myocarditis, 
• active angina, 
• documented history of sustained ventricular tachycardia (>15 
seconds), 
• symptomatic non-sustained ventricular tachycardia (NSVT), 
• second or third degree atrioventricular block, 
• symptomatic peripheral vascular disease, 
• chronic obstructive pulmonary disease, 
• asthma, 
• long term alcohol or drug abuse, 
• chronic renal (serum creatinine > 200 |Limol/L), hepatic, 
hematological, neurological or collagen vascular disease 
5.3.3 Study Measurements 
Baseline measurements included assessment of symptoms using the 
Minnesota Heart Failure Symptom Questionnaire (Rector, Kubo et al. 1987) and 
clinical examination: pulse, heart rate, blood pressure sitting and standing, 
examination of jugular venous pressure, position of apex beat, presence or absence of 
heart murmur or lung rales. A six-minute corridor walk test was carried out as 
described by Yusef et al. (Yusuf and Tsuyuki 1996). Standard 2-D Doppler 
echocardiography was carried out. Routine radionuclide ventriculography (MUGA) 
at rest was performed. Results were considered to be unreliable in four patients in 
the metoprolol group and five in the celiprolol group due to arrhythmias. All 
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recordings were satisfactory in the placebo group. Natriuretic peptides (atrial 
natriuretic peptides and brain-ventricular natriuretic peptides) were assayed as 
previously described by Sanderson et al. and Yu et al. (Sanderson, Chan et al. 1995; 
Yu, Sanderson et al. 1996). 
/ 
Assessment of HRV: 24-hour ambulatory ECG (Holter) monitoring was 
carried out in all patients for the assessment of arrhythmias, hourly heart rate and 
HRV (Marquette Holter System), but the four patients with pacemaker had excluded 
for HRV analysis. Standard time-domain measurements and average 24 hour 
spectral values for LF, HF and VLF bands were made. Recordings were done at 
baseline and repeated after 12 weeks of therapy. All analyses were done personally 
be me. 
5.3.4 Statistical Analysis 
Differences between the treatment groups were evaluated by repeated 
measures analysis of variance for continuous variables (ANOVA)，with Bartlett's 
test for homogeneity of variances and Tukey-Kramer multiple comparison test if p < 
0.05. Within group differences were tested using a paired t-test, Wilcoxon signed 
rank test for non-parametric data, or Chi-square test for discrete variables. 
For comparison of baseline variable all patients were included. For 
comparison of 12 weeks data with baseline only those patients still in the trial were 
analysed. Results are expressed as mean value 士 SEM. Differences were considered 
significant if the probability (p) value was < 0.05. 
5.3.5 Results 
Baseline Characteristics - Fifty patients were recruited in this study and were 
randomized to receive metoprolol therapy (n=19), celiprolol therapy (n=21) or 
placebo (n=10). Their baseline demographics are shown in Table 7，page 69. The 
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treatment groups did not differ significantly with respect to gender, etiology, NYHA 
functional class, symptom questionnaire score, exercise tolerance (6 min. walking 
test), baseline blood pressure sitting and standing, heart rate, left ventricular ejection 
fraction by radionuclide ventriculography, left ventricular end diastolic dimension, 
/ 
fractional shortening, levels of natriuretic peptides (ANP and BNP)，frusemide 
dosage and number of patients taking ACE inhibitors or nitrates. 
The age of the metoprolol group was significantly different from the 
celiprolol group but not different compared to placebo. This was due to one young 
patient who was recruited into the metoprolol group. 
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Table 7 Baseline Clinical Characteristics of Study Patients 
Metoprolol Celiprolol Placebo P value 
Group Group Group  
(n=19) (11=21) (n=10)  
Age (yr.) 56.1±2.8*^ 67.1±2.1*^ 61±2.9竹 * 0 .008/ 0.28,^0.11 
Range 20-72 45-82 47-76 
Gender 
Male 16 13 9 
Female 3 8 1 
Etiology 
IDC 10 8 2 
ICM 7 10 5 
HTHD 2 3 3 
NYHA Functional 
Class 
II 8 9 5 
III 11 10 5 
IV 0 2 0 
Mean NYHA Class 2.6±0.12 2.7±0.15 2.5±0.18 0.65 
Symptom 18.1 土 3.5 13.5±2.7 7.7±2.9 0.12 
Questionnaire Score 




Sitting 114 士 5/70 士 3 113 士4/71士2 105 士 6/65 士3 0.48/0.35 
Standing 119±6/76±3 114±4/74±2 107 士 6/68±4 0.37/0.2 
Heart Rate (bpm) 79.3士2.5 77.9+2.8 79.5+3.5 0.91 
LVEF - MUGA (%) 26.9 土 3.1 30.2±2.7 33.1+4 0.42 
LVedd(cm) 7.2±0.3 6.9±0.3 6�7±0.2 0.55 
FS (%) 14.4士1.3 15+1.1 18+1.5 0.19 
ANP (pg/mi) 141.4±32.9 193.4±73.5 269.4±187.7 0.64 
BNP (pg/ml) 151.9+22.8 166.4±36.1 128.3+24.8 0.73 
Treatment 
Frusemide dose(mg) 85.3 士12.7 56.5±8.6 66土 13 0.16 
ACEI 16 (84%) 15(71%) 10 (100%) 
Nitrates 10 (53%) 14 (67%) 3 (30%) 
Values are means 士 SEM 
IDC = idiopathic dilated cardiomyopathy; ICM = ischemic cardiomyopathy; HTHD 
=hypertensive heart disease; NYHA= New York Heart Association; ETT = exercise 
tolerance test; LVEF = left ventricular ejection fraction; LVedd = left ventricular end 
diastolic dimension; FS = fractional shortening; ANP = atrial natriuretic peptides; 
BNP = Brain (ventricular) natriuretic peptide; ACEI = angiotensin converting 
enzyme inhibitors. 
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Withdrawals and tolerabilitv - Two patients in the metoprolol group were 
withdrawn at week 3 and 5 for increasing chest tightness, fainting attacks and 
generally feeling unwell. Four patients in the celiprolol group did not complete the 
randomized period, two patients died at 5 and 11 weeks respectively. Two patients 
were withdrawn at 1 and 3 weeks because of nausea and increasing angina. Two 
patients were withdrawn from the placebo group, one with angina and one because of 
increasing heart failure but there were no deaths in the placebo group during the 
double blind period. Three patients in the metoprolol group were unable to tolerate 
the full dose (50 mg. twice daily) and were maintained on 25 mg. twice daily (two 
patients) or 50 mg. morning and 25 mg. in the evening. All but one patient tolerated 
the full dose of celiprolol. Compliance was otherwise good. 
Symptoms - The results of the symptom questionnaire score and NYHA 
functional class are shown in (Table 8, page 72). Metoprolol was associated with a 
significant reduction in a symptom score (p=0.003). Celiprolol was associated with a 
similar but smaller improvement (p = 0.018) but there was no significant difference 
between metoprolol and celiprolol. There was no significant change in symptoms in 
the placebo group (p = 0.6) (Figure 12，page 71). Similarly NYHA functional class 
improved significantly in the metoprolol group from 2.6 土 0.12 at baseline to 1.94 士 
0.13 (p = 0.001). There was no change in the placebo group, and a small but non-
significant reduction in the celiprolol group (p= 0.11). 
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• • Placebo 
10.0] * min Metoprolol 
^ Celiprolol 
i i m 
P M C 
Figure 12 Reduction in symptom score after 12 weeks of placebo (P), 
metoprolol (M)，or celiprolol (C) treatment. 
*p = 0.073 V placebo. 
Exercise Capacity (6 min. walk test) (Table 8, page 72) - There was a 
significant increase in exercise capacity on metoprolol, as judged by distance 
covered, from 1246 士 54 to 1402 士 52 feet (p = 0.0006). A smaller improvement 
was seen with celiprolol (1191 ± 55 to 1256 土 61 feet: p = 0.049). There was a non-
significant change in the placebo group. However, the mean increase in distance for 
metoprolol and celiprolol were not significantly different from the placebo group. 
The mean increase in exercise distance with metoprolol was 154 ± 39 feet compared 







































































































































































































































































































































































































































































































































Left Ventricular Systolic Function (Table 9, page 73) - Left ventricular 
ejection fraction measured by radionuclide ventriculography rose significantly in the 
metoprolol group from 26.9 土 3.1 o/o to 31 土 3.4% (p = 0.016). In the celiprolol group 
the mean from 30.2 土 2.1o/o at baseline to 36.6 土 3.8o/o at 12 weeks but this was 
/ 
statistically not significant (p=0.2). The median left ventricular ejection fraction was 
32% at baseline and 33% at 12 weeks. There was a significant fall in left ventricular 
ejection fraction in the placebo group (p=0.047). 
Compared to placebo the increase in LVEF was significant for both 
metoprolol and celiprolol (p=0.005 and p=0.03 respectively, (Figure 13, page 74) but 
there was no significant difference between celiprolol and metoprolol. Echo derived 
fractional shortening showed a trend to increase in the metoprolol group (p=0.09) 
with no significant change in celiprolol group (p=0.23). Despite these improvements 
in left ventricular systolic function, left ventricular end diastolic dimension did not 
change significantly in any group. 
Table 9 Change in LV Size and Systolic Function between Weeks 0 and 12 
Metoprolol Celiprolol Placebo 
Week 0 12 0 12 0 12 
LVEF (%) 26.9士3.1 31±3.4t 30.2±2.7 36.7±3.8 33.1±4 29±2.8t 
FS (%) 14.4+1.3 17士 1.3 15±1.1 17.8±1.5 18士 1.5 19土2.2 
LVEDD 7.2士0.3 7.2 士0.2 6.9+0.3 6.7±0.3 6.7±0.2 6.8±0.2 
(cm)  
Values are mean 士 SEM 
t = p<0.05. 
FS, fractional shortening; LVEDD, left ventricular end diastolic dimension; LVEF, 
left ventricular ejection fraction 
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• • Placebo 
_ Metoprolol 
10-1 * 圓 Celiprolol 
— ^ + g, p II ^ . �I I 
1 
Figure 13 Changes in Left Ventricular Ejection Fraction (LVEF) after 12 
Weeks of Placebo (P), Metoprolol (M)，or Celiprolol (C) Treatment 
*p = 0.0049,卞p = 0.028 V placebo. 
Natriuretic Peptides - Although there was an initial fall in atrial natriuretic 
factor concentrations in both metoprolol and celiprolol groups at eight weeks 
compared to baseline, by 12 weeks the differences were non significant. BNP 
showed little change in any patient group between baseline and 12 weeks, although 







































































































































































































Holter Analysis - At baseline there was no significant difference in heart 
rates between the three treatment groups throughout the 24-hour period. However, 
after 12 weeks of treatment there was significant reduction in resting heart rate in the 
metoprolol group (p<0.001) (Figure 14，page 77). There was no significant change 
/ 
in either the placebo or the celiprolol groups, either in resting heart rate or 
throughout the 24 hour period (Figure 14，page 77), and the difference between 
metoprolol and celiprolol was significant (p<0.001). 
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Figure 14 24 hour heart rate (Holter) analysis at baseline and after 12 weeks of 
treatment with placebo (P), metoprolol (M)，or celiprolol (C). 
77 
Heart Rate Variability analysis: (Table 11，page 79) - Despite these obvious 
improvements in clinical parameters and LV ejection fraction with metoprolol in 
particular there was little change in the spectral analysis of HRV. However there 
was a significant improvement (prolongation) of SDNN and SDANN and SD from 
the time-domain analysis after 12 weeks of treatment with metoprolol. There were no 
significant changes with celiprolol. There was no relationship between the 












































































































































































































































































































































































































































































































































































































































































This study was the first to directly compare metoprolol with a third 
/ 
generation vasodilating (3 blocker in the treatment of CHF. We were unable to 
demonstrate any significant differences between the vasodilating P blocker celiprolol 
and metoprolol compared to placebo with long-term treatment despite the apparent 
superiority of celiprolol during the initiation of therapy (Sanderson, Chan et al. 
1995). 
In contrast, many of the results suggest that metoprolol may be more 
effective, with clearer improvements in symptoms, exercise capacity and LV ejection 
fraction compared to baseline, and significant improvement in LV ejection fraction 
compared to placebo. 
Celiprolol has actions that are theoretically attractive for the treatment of 
heart failure, though there may be concern about the P-2 agonist activity because in 
heart failure the P_i/p-2 ratio is reduced; however, this is due to a relative, rather than 
an absolute increase in numbers of P-2 receptors (Hall, Ferro et al. 1993), and it is 
unclear whether these changes are functionally important. Nevertheless, it seems 
that the recognized vasodilating activity of celiprolol does not improve symptoms or 
systolic function compared to P blockade alone, and this underlines the importance 
of p blocking functions. 
The major difference we observed between the two drugs was the markedly 
different effect on heart rate. It is difficult to be sure whether this was due to the p-2 
agonist activity of celiprolol or reflected its vasodilating action. The final dose given 
to the patients (200mg daily) has been shown to be effective in hypertension and 
angina, so that under-dosing is unlikely to be the explanation. However, the effect of 
p-blockers on the heart rate alone may be their most important property in heart 
failure (Yamakawa, Takeuchi et al. 1996). It is possible that a simple reduction in 
heart rate will improve ventricular filling and this secondarily leads to improved 
systolic function by a change in geometry of the heart. The lack of a significant 
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effect of celiprolol on 24-hour heart rate may explain its poorer effect on the other 
variables. It is likely that a reduction of heart rate is at least one of the major reasons 
for the benefit of P-blockers in heart failure. 
/ 
It is interesting that SDNN was prolonged by treatment with metoprolol in 
this group of patients. In the UK Heart study SDNN was the most powerful 
predictor of the risk of death due to progressive heart failure (Nolan, Batin et al. 
1998). A SDNN <50ms was associated with an annual mortality rate of 51.4%. The 
SDNN index is modulated predominantly by low-frequency cyclical changes which 
in part reflect thermoregulatory mechanisms, fluctuations in activity of the rennin-
angiotensin system, and the function of peripheral chemoreceptors (Malliani, Pagani 
et al. 1991; Ponikowski, Chua et al. 1996). The reduction of SDNN in heart failure 
is thought therefore to reflect the summed influence of these abnormalities as well as 
changes in respiratory pattern and physical inactivity in heart failure. We could not 
relate directly the changes in HRV with the improvement in LV ejection fraction or 
symptoms. However, in the UK-HEART study the SDNN index was not strongly 
related to simple measurements of LV systolic function. 
Limitations of this Study — Our study had a small number of patients and 
there is a possibility of a type II error. The small number of placebo patients and the 
wide scatter of values meant that many potential differences did not reach statistical 
significance and because of this the advantages of both the P-blockers versus placebo 
may have been underestimated. 
However, this study was not designed for detecting small changes (which 
may by themselves be significant) but to determine whether celiprolol had any 
clinically significant advantages over metoprolol, particularly in terms of symptoms, 
exercise capacity, ejection fraction and heart rate variability. 
5.3.7 Summary 
In summary, in this study we have confirmed the beneficial effects of 
celiprolol in patients with but were unable to demonstrate any significant advantages 
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of a vasodilator P-blocker over metoprolol. However, there was a significant 
difference in their effects on heart rate. This would suggest that newer P-blockers 
with additional vasodilator properties may not have significant advantages for relief 
of symptoms compared to metoprolol, and indicates that perhaps the most important 
property of these agents is the adrenergic blockade and the subsequent reduction in 
heart rate. 
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5.4 Effect of P-Blockade on Baroreceptor and Autonomic Function 
in Heart Failure-Assessment by Short Term Spectral Analysis. 
5.4.1 Trial Design and Study Patients 
In this study a sub-group of subjects from the above study had in-depth 
studies using the spectral analysis technique as described previously. The 
interventions and patients of the study were as described above (in Section 5.3.1, 
page 65) 
5.4.2 Recording Technique and Protocol 
The recording technique was performed the same as described in the previous 
study "Impact of changes in respiratory frequency and posture on power spectral 
analysis of heart rate and SBP variability in normal subjects and patients with heart 
failure" (see section 5.1.2, page 42) 
Recordings were taken in 5-7 minute periods during spontaneous respiration 
and controlled breathing at 15 breaths per minute supine and standing. Depth of 
breathing or tidal volume was not controlled and subjects were allowed to breathe 
comfortably to avoid disturbances of acid-base balance. Recordings from the 
controlled respiration period were used for analysis in order to standardize the 
respiratory input (Sanderson, Yeung et al. 1996). 
5.4.3 Signal Acquisition, Power Spectral Analysis and Cross Spectral Analysis 
All these were applied as described in section 5.1.3，page 42, section 5.1.4, 
page 43 and section 5.2.2, page 57，Figure 6，page 45 and Figure 9，page 58. 
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5.4.4 Reproducibility 
Reproducibility of spectral analysis of heart rate, blood pressure variability 
and the a angle was assessed in five normal subjects and five patients with heart 
failure, supine and erect, with controlled respiration of 15 breaths/min. Recordings 
were repeated on three consecutive days under the same time and at identical 
conditions. 
5.4.5 Statistical Analysis 
Data is expressed as mean 士 SEM. For paired data the paired t-test and 
Wilcoxon signed rank test were used, and for non-paired data either the unpaired 
Student t-test or the Mann-Whitney U-Test were used. One-way ANOVA with 
correction for baseline differences was performed using the non-parametric Kruskal-
Wallis test. A value of P < 0.05 was considered significant. 
5.4.6 Results 
Four patients had permanent pacemakers and were excluded. Satisfactory 
spectral data on each occasion were obtained in eleven patients in the metoprolol 
group, fourteen in the celiprolol and seven in the placebo groups. The clinical details 
of these subjects are shown in (Table 12，page 85) 
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Table 12 Baseline Clinical Characteristics of Study Patients 
Metoprolol Celiprolol Placebo p value 
group group group  
(n=ll) (n=14) (n=7)  
Age (years) 53.1 (4.2)* 64.9(2.5) 60.1 (3.4) 
Range 20 to 68 45 to 80 47 to 76 
Sex 
Male 11 11 7 
Female 0 4 1 
Etiology 
Idiopathic dilated 5 7 2 
cardiomyopathy 
Ischaemic cardiomyopathy 6 7 4 
Hypertensive heart disease 0 1 2 
NYHA functional class 
II 4 7 4 
III 7 6 4 
IV 0 2 0 
Mean NYHA class 2.6 (0.15) 2.7 (0.19) 2.5(1.9) 0.82 
Symptom questionnaire score 19.3 (5.0) 14.9 (3.6) 6.9 (3.1) 0.16 
Exercise tolerance test (6 min 1288 (45) 1214(63) 1315 (86) 0.53 
walk, feet) 
Baseline blood pressure (mmHg) 
Sitting 117(9)/72(4) 111(5)/71(3) 109(6)/66(4) 0.70/0.54 
Standing 120(9)/79(3) 112(5)/75(3) lll(6)/68(5) 0.59/0.12 
Heart rate (beats/min) 82 (3.5) 81.5 (3.3) 78.6(4.0) 0.82 
Left ventricular ejection (%) 23.6 (5.3) 30 (3.2) 36.3 (4.3) 0.15 
Left ventricular end-diastolic 7.7(0.3) 7.1(0.3) 6.8 (0.3) 0.19 
dimension (cm) 
Fractional shortening (%) 15 (2.0) 14.4 (1.3) 19.4 (1.5) 0.11 
Atrial natriuretic peptide (pg/ml) 119 士 20 214 土 104 312 土 235 0.61 
Brain natriuretic peptide (pg/ml) 173 ±37 157 ±50 130 土 27 0.81 
Treatment 
Frusemide dose (mg) 97.8(18.7) 58.2 (12.5) 67.5(16) 0.19 
ACEI (% receiving) 9 (82%) 12 (80%) 8(100%) 
Nitrates (% receiving) 5 (45%) 8 (53%) 2 (25%) 
Values are means (SEM) unless otherwise stated. Abbreviations: ACEI, angiotensin 
converting enzyme inhibitors; NYHA, New York Heart Association. Statistical 
significance: * p< 0.04，metoprolol compared with celiprolol. The difference 
between metoprolol and placebo, and between celiprolol and placebo, was not 
significant. 
Spectral Analysis of Heart Rate and Systolic Blood Pressure Variability 
(Table 13，page 87 & Table 14，page 88) - In the metoprolol group there was a 
significant increase in the supine R-R interval and variance from week 0 to week 12, 
associated with an increase in HF power (all: p < 0.01). There were no significant 
changes in the celiprolol or placebo group. 
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However, HF power in the metoprolol group at 12 weeks was not 
significantly different from placebo, probably due to the small numbers and large 
range of values in both groups. 
/ 
For SBP variability there was a trend for LF power (expressed as nu) to 
increase with metoprolol therapy and a similar trend was seen with placebo but there 
were no significant changes with celiprolol therapy. 
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Table 13 Heart Rate (R-R) Variability Measured with Paced Respiration (15 
breaths/mins) 
Mean Variance LF HF LF HF L F / H F ~ 
(ms) (ms) (ms2) (ms^) (nu) (nu) 
Metoprolol Therapy 
WeekO 
Supine 763±39.2 286+45.8 35.1±14.0 87.1 土 21.3 18.3±4.4 54.5土4.8 0.35±0.1 
Standing 692土34.3 280±52.6 27.6±20.3 62.8±26.4 11.4 土6.0 46.4±6.2 0.35±0.2 
Week 4 
S u p i n e 967±49.0 7 5 9 ± 2 1 4 43.3±18.7 260±64.3 11.3 土 3.1 70.8±6.2 0.16+0.1 
S t a n d i n g 8 9 3士 5 0 . 5 755士230 87.6士61.5 299±141 10.6+3.3 63.7士 7.0 0.2±0.1 
Week 8 
S u p i n e 998+60.5 862+354 7 2 . 5 + 4 2 . 2 246±84.8 11.7+3.1 70.3±7.4 0.2+0.1 
S t a n d i n g 895±59.3 638±233 51.2±25.8 2 5 0 + 1 3 0 13.8+5.3 60.9土 8.5 0 . 4 ± 0 . 2 
Week 12 
Supine 1039±47.6* 572±143* 60.4±24.3 185土44.0* 16.4±3.6 72.5+4.4* 0.2±0.1 
Standing 965±49.8 809土192 47.0±24.9 330±136 10.3±2.9 70.6±6.4 0.2±0.1 
Celiprolol Therapy 
WeekO 
Supine 840±33.8 576±151 94.7±40.1 187+74.6 24.7+6.1 51.2士 7.5 0.9±0.4 
Standing 808±47.2 626士192.7 25.2±11.8 197 土 96.2 12.7±3.6 52.6士 6.6 0.3士0.1 
Week 4 
Supine 931+57.0 493土123 41.4±13.0 159±40.0 22.5±6.6 62.8±7.9 0.810.5 
Standing 894±57.1 575±160 61.8±46.2 163±67.9 11.6±2.6 67.0±4.3 0.2 土 0.1 
Week 8 
Supine 885±54.8 726.2±263 73.7±32.2 143土60.7 25.5±8.1 55.0±6.8 0.7 土 0.3 
Standing 868±60.6 719±349 62.1±36.7 267±177 17.2±3.0 58.7土4.5 0.3±0.1 
Week 12 
Supine 887±49.7 1432+639 84.2+38.5 258+70.9 23.2±5.4 60.5±6.7 0.5+0.2 
Standing 884土61.8 732土391 77.8±51.7 261±192 20.7±6.8 62.1 土 5.7 0.5+0.2 
Placebo Therapy 
WeekO 
Supine 841±62.5 458±134 25.4士 12.2 240±81.1 9.3±3.1 68.7 土 6.1 0.1 士 0.1 
Standing 795±47.3 399+102 17.7+5.2 130151.5 12.5±4.4 59.4+7.4 0.2士 0.1 
Week 4 
Supine 938±44.3 806±225 41.4±18.2 213.6±76.7 11.2±3.2 67.4±5.2 0.2±0.1 
Standing 842±46.1 369±110 63.6±60.7 119 士 59.2 16.7 土 12.7 65.8士 12.1 0.7 士 0.6 
Week 8 
Supine 915±74.0 1245士353 97.6土56.1 348±123 10.7±4.15 74.5±12.2 0.2±0.1 
Standing 855士 103 816±348 125±89.3 256±86.4 23.7±10.7 61.0±9.2 0.5+0.3 
Week 12 
Supine 944±66.2 723土188 42.8±15.1 240土 110 17.2 土4.3 68.5士 7.7 0.3±0.1 
Standing 887±88.2 478±113 59.5±38.7 166±66.2 18.6±9.3 66.0±11.8 0.4 士 0.3 
* p< 0.01 (week 12 versus week 0); LF, low-frequency power; nu, normalized units. 
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Table 14 Systolic Blood Pressure Variability Measured with Paced Respiration 
(15 breaths/mins) 




Supine 117+6.5 22.0±4.7 1.2+0.8 5.4±1.9 12.9±5.6 66.7±8.8 0.4±0.3 
Standing 112±7.5 41.6±11.3 0.9 土 0.4 9.5士1.8 4.5±1.9 69.8±6.2 0.1 ±0.03 
Week 4 
Supine 109 士 4.2 18.2 土 3.6 0.8±0.5 5.0±1.3 13.2 士6.3 75.8±8.2 0.3 士 0.26 
Standing 116 土9.6 22.8±5.5 1.5±0.9 7.3±2.5 16.6 士7.7 67.5±7.1 0.5士0.3 
Week 8 
Supine 108 士5.5 70.9±45.9 6.1土4.7 5.3 土 1.2 21.8±11.3 66.6土 11.0 1.4 士 1.0 
Standing 116 土10.5 32.5±6.9 3.2 士 1.9 8.5 士2.4 24.8±10.4 56.1±10.4 1.1±0.7 
Week 12 
Supine 110±6.1 22.7±4.2 2.4±1.2 4.0 土 1.0 31.3±10.0 59.7±9.4 2.3±1.6 
Standing 109 土6.9 55.1±16.4 3.2 土 2.6 9.6+4.0 18.5±9.6 73士9.1 0.9±0.7 
Celiprolol Therapy 
Week 0 
Supine 115士3.7 49.6±26.7 3.4士1.6 6.3±1.1 20.1±5.7 69.4±5.6 0.5±0.2 
Standing 111±3.8 48.4±18.2 1.7±1.2 9.5土4.1 14.4+4.0 53.4土 8.1 0.4±0.1 
Week 4 
Supine 107±4.3 35.0±10.2 1.7±0.9 8.2±4.2 14.1±5.7 81.1 土 5.8 0.3±0.2 
Standing 104±4.6 35.0士14.3 2.7±1.4 4.4±1.0 20.815.8 66.7土 6.5 0.5±0.2 
Week 8 
Supine 114±6.1 30.0±7.3 4.1 士 2.6 11.6 土4.6 21.4±8.6 68.5±7.5 0.6±0.3 
Standing 105+6.2 42.0±16.0 0.4士0.2 6.6 土 1.5 7.8±2.2 81.7士3.1 0.1士0.03 
Week 12 
Supine 109±4.7 53.9土20.3 2.0土 0.6 11.9 土 6.5 18.6±5.0 73.415.4 0.3±0.1 
Standing 107 士4.8 27.0±5.9 7.3+4.3 4.3±1.0 35.7±11.1 57.7 土 10.1 1.9±1.0 
Placebo Therapy 
WeekO 
Supine 110110.3 36.2±9.4 2.4 土 1.8 8.1 ±4.0 16.1 士2.5 65.1 土 7.3 0.3 土 0.1 
Standing 108±8.7 44.4士 16.4 0.8±0.4 5.4±2.4 19.6±8.9 56.4+9.9 0.6±0.3 
Week 4 
Supine 129.8±11.1 50.2±8.6 0.6士0.2 5.5±1.2 11.8±5.2 81.4±4.0 0.2±0.1 
Standing 110 土7.9 46.4±19.8 0.8±0.4 3.3 土 0.3 14.4±6.6 70.4土6.0 0.25土 0.14 
Week 8 
Supine 104±15.6 155 土65.2 7.3±3.7 12.5士4.9 25.4±11.5 67.8±12.0 0.7 土 0.5 
Standing 112±14.7 80.2±34.1 6.8±6.1 4.7 土2.0 40.2±18.0 54.1 土 17.7 1.6±0.9 
Week 12 
Supine 104士7.3 240±206 7.1±3.1 11.6±8.7 45.5土 11.2 50.2+9.2 1.3土0.5 
Standing 94.8士9.3 47.7士30.0 3.5±1.3 3.2 土1.8 60.2士 9.7 35.2士10.0 2.4 土 0.9 
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Cross Spectral Analysis (Table 15, page 90 & Fig. Figure 9，page 58) - In all 
the patients with heart failure, baroreceptor gain was significantly depressed 
compared with the normal group (4.95 士 0.55 ms/mmHg versus 11.73 土 1.32 
ms/mmHg, p < 0.0001). 
In the metoprolol group, a angle increased significantly from week 0 to week 
12 (supine 4.5 士 1.05 to 9.06 土 1.6 ms/mmHg; p = 0.03; standing 2.2 士 0.45 to 7.6 
ms/mmHg p = 0.009). This effect was apparent after 4 weeks of treatment (Figure 
15，page 91). 
In contrast, the changes in a angle in the celiprolol or the placebo group were 
not significant (Table 15, page 90). 
By using Kruskal-Wallis one way ANOVA (non-parametric) for comparison 
of all three groups for a angle changes from baseline to week 12, p = 0.08 for supine 
and p = 0.5 for standing (two-tailed). By one-way ANOVA (parametric) for a angle 
(supine) week 12-0，F=0.69. However, using a nonparametric independent t-test, 
the effect of metoprolol was significantly greater than celiprolol on a angle (supine) 
from baseline to week 12 (p = 0.04). 
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Table 15 a Angle Measured with Paced Respiration (15 breaths/mins) 
WeekO Week 4 Week 8 Week 12 
Metoprolol 
/ 
Supine 4.5±1.05 8.6土 1.6 6.7±1.4 9.1±1.6* 
Standing 2.2±0.45 7.6±2.2 9.0 土 4.5 7.6±2.4* 
Celiprolol 
Supine 5.0±1.1 6.3±1.1 4.7 土 1.2 6.1±1.2(NS) 
Standing 7.2 土 2.8 5.5 士 1.0 5.3±1.1 6.2±1.7(NS) 
Placebo 
Supine 6.5士 1.5 6.5±1.6 5.2±1.5 5.47士 1.6 (NS) 
Standing 7.3±2.8 5.4±1.1 8.1 土 1.4 9.1±3.0(NS) 
* p < 0.05; NS, non significant (week 12 versus week 0). 
At baseline, there was no significant difference of a-Angle measured in 
supine or standing position between groups. 
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Figure 15 Change in HF a angle (A aHF) from baseline at weeks 4，8 and 12， 
measured in the supine and standing positions with paced respiration (15 
breaths/min) in the three treatment groups 
Values are means 士 S.E.M. metoprolol; celiprolol; placebo. Supine: * p = 
0.03 compared with baseline. Standing: *p = 0.009 compared with baseline. 
91 
Reproducibility - The repeatability of the measurements is shown in (Table 
16，page 92); values are expressed as mean 士 SD. In patients with CHF the mean 
difference in absolute units for the measurement of a angle was 0.12 ± 0.13 in the 
supine position and 0.32 土 0.15 in the standing position. 
Measurement of HF (nu) mean difference in absolute units was 3.2 士 1.5 
supine and 3.75 士 2 while standing. However the reproducibility of the SBP 
variability in the LF band was poor (approximately 20% mean difference), but in the 
HF band it was 15 士 17% supine and 6 士 7% standing. 
Table 16 Repeatability Measurements 
Mean RR-LF RR-HF SBP-LF S B P - H F S l F 




absol A 35±24 2.7±3.5 3.2±1.5 4.9±4.3 7.2 土 5.0 0.12士0.13 
% A 4.2±2.7 8.4+7.3 6.2±1.8 22.7土 19.6 15.7±17 3.2±2.4 
standing 
absol A 29土22 2.1±1.9 3.7±2.0 3.8土4.6 4.1±5.3 0.32±0.15 
% A 3.8±2.9 18.4+14.3 5.5+3.3 24.2+29.8 6.0+7.7 9.9土7.4 
Normals 
Supine 
absol A 25+12 1.4土0.53 2.4±1.5 6.8±2.0 5.4±3.4 1.2811.4 
% A 2.9土 1.5 2.9±0.12 3.45±1.5 16.7土6.0 10.7土9.5 6.1 土4.0 
standing 
absol A 13土7 4.1±4.6 3.5+2.9 1.1±1.0 1.9±2.2 0.4+0.4 
% A 1.6±0.6 11.7±11.3 6.5±4.5 2.5±1.5 3.2±2.8 5.2±4.7 
Values are means 士 S.D. Absol A= absolute differences between repeated recordings 
in measurement units; %A= percentage differences. 
Haemodynamics and clinical data _ The full results of the effect of celiprolol 
and metoprolol on various clinical parameters are reported elsewhere (Sanderson, 
Chan et al. 1998) and in part above. In summary, in the metoprolol group after 12 
weeks of therapy there was a significant reduction in symptom score (p<0.001) and 
an improvement in NYHA (New York Heart Association) class (p<0.001), exercise 
distance (p<0.001) and LV ejection fraction (p=0.016) compared to baseline. 
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In the celiprolol group there was a reduction in symptom score (p=0.02), less 
improvement in exercise distance (p=0.05) and no significant changes in NYHA 
class, LV ejection fraction or heart rate. 
/ 
However, there were no significant differences between celiprolol and 
metoprolol apart from heart rate. Thus the vasodilator properties of celiprolol did not 
appear to provide any obvious additional benefit and overall, metoprolol appeared to 
have a superior effect. 
5.4.7 Discussion 
In this study we found that metoprolol did increase HF power suggesting an 
increased vagal activity. This was not found in the previous study which utilized the 
standard technique based on 24 hour ambulatory ECG monitoring. It is not clear 
why this is so but probably is due to more controlled conditions during the recording 
period in this study. 
Use of the a index as a measure of baroreflex gain appears to be justified 
because it has been shown to correlate significantly with the standard phenylephrine 
test in hypertensive patients (Pagani, Somers et al. 1988) as well as in normal 
subjects (Bablar, Yamamoto et al. 1995) and to be reproducible (lellamo, 
Legramante et al. 1996). The a angle tends to produce higher values than the 
pharmacological techniques. Partly this may be due to the comparatively slower 
onset of the baroreflex sensitivity stimulus with pharmacological techniques and 
possibly because spectral techniques more accurately reflect the spontaneous activity 
of the arterial baroreflex at rest rather than during artificially stimulated conditions. 
The use of paced respiration may further improve the analysis by introducing 
a controlled perturbation to the system as described in my first study (Sanderson, 
Yeung et al. 1996). In this study we found the reproducibility of the a index over 
three successive measurements to be acceptable. 
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Using standard techniques, baroreflex fiinction as measured by the gain of the 
arterial pressure-heart rate relationship, has been shown to be impaired in heart 
failure (Ferguson, Abboud et al. 1984; Creager 1992; Ferguson, Berg et al. 1992; 
Osterziel, Hanleim et al. 1995). Using spectral techniques we have also found that 
/ 
baroreceptor gain is reduced in heart failure. 
The precise mechanisms that cause these abnormalities in arterial 
baroreceptor dysfunction have not yet been clearly defined (Creager 1992). Reduced 
sensitivity may result from abnormalities in the arterial baroreceptors nerve endings 
and the afferent neurons, changes in arterial compliance, altered central mechanisms, 
impaired transmission of sympathetic and parasympathetic afferent neurons or 
reduced sinus node responsiveness. There is some evidence, that central 
mechanisms are involved for parasympathetic and sympathetic outflow (Van de 
Borne, Montano et al. 1977; Porter, Eckberg et al. 1990; Rahaman, Kara et al. 1995). 
However, recent work suggests the possibility that baroreceptor control of muscle 
sympathetic activity in congestive heart failure may be active and indeed rapidly 
responsive (Ando, Dajami et al. 1997). 
If autonomic and baroreceptor dysfunction in heart failure is at least partly 
centrally mediated then those P blockers that cross the blood-brain barrier may have 
an advantage (Rahaman, Hara et al. 1995). In this study there was a difference 
between metoprolol and celiprolol that may be explained in part by the fact that 
celiprolol is hydrophilic and does not cross the blood-brain barrier to any significant 
extent whereas metoprolol is lipophilic. 
However, there are other possible explanations. Celiprolol has some degree 
of intrinsic sympathomimetic activity with a mild Pa-receptor agonist activity 
(Prichard 1992) and this may be relevant in terms of up-regulation of P-receptors in 
the sinus node and improved sinus node responsiveness as discussed above. 
However, the P blocking activity of celiprolol is greater than its intrinsic sympatho-
mimetic activity as shown by a trend towards the increased R-R interval and 
increased R-R variance and its effectiveness as an anti-anginal agent (Dunn and 
Spencer 1995). 
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Nevertheless, the reduction of heart rate was greater with metoprolol than 
celiprolol and an alternative explanation for the greater efficacy of metoprolol is that 
gain of the heart rate-SBP relationship is proportional to the basal heart rate and that 
merely reducing the heart rate will increase the gain. However, Floras et al (Floras, 
Vaim Jones et al. 1988) found that the increases in baroreflex sensitivity with either 
acute or chronic P-blockade were unrelated to the effects of these drugs on heart rate. 
Furthermore, the basal heart rate in the metoprolol group was slightly higher 
(non-significant) while the a angle was lower compared with the celiprolol group, 
indicating that heart rate itself is not a primary determinant of the a angle. It is 
unlikely, therefore, that the differences between metoprolol and celiprolol are only 
due to their differing effects on the sinus node and heart rate. The lack of a 
significant effect of celiprolol on heart rate could equally be due to the reflex 
tachycardia consequent on celiprolol direct vasodilatation action as well as a P2-
agonist effect on heart rate. 
The clinical aspects of this study were outlined in the previous study 
(Sanderson, Chan et al. 1998) and although metoprolol appeared to be marginally 
superior in terms of symptoms, exercise capacity and ejection fraction, there were no 
significant differences between metoprolol and celiprolol apart from the changes in 
heart rate. 
Other explanations for the effectiveness of metoprolol apart from its central 
actions include increased aortic baroreceptor afferent nerve discharge due to altered 
viscoelastic properties (Angell-James 1973) or reduced renal renin levels and 
consequently levels of angiotensin which is known to blunt baroreflex regulation. 
(Mace, Watson et al. 1985). Atenolol, a hydrophilic p-blocker, has been shown to 
increase the a angle index in subjects with hypertensive (Lucini, Pagani et al. 1994). 
These peripheral actions of P-blockers may also be important. 
As this was a parallel group study with relatively small numbers there is an 
increase chance that the baseline values may not be comparable. The mean heart rate 
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in the metoprolol group was higher than in either celiprolol or placebo but this was 
not statistically significant. 
Similarly, the a angle at baseline in the metoprolol group on standing 
/ 
appeared to be lower than the celiprolol and placebo groups although the supine 
value at baseline was not significantly different between three groups. Although 
there was a trend for the metoprolol group to have a higher symptom score, lower 
LV ejection fraction and higher LV end-diastolic dimension on echocardiography, 
none of these differences were statistically significant. 
Secondly, we suggest that the increase in HF power in the metoprolol group 
reflects an increase in vagal activity. However, an element of the HF power is 
mechanically mediated by respiration (between 2 to 7%) (Bernardi, Salvucci et al. 
1990), but it is difficult to conceive how the two p-blockers would differentially 
affect this component directly. P-blockers may affect skin blood flow and this could 
affect the measurement of SBP via finger photoplethysmography, reducing the 
ability to detect a significant change in baroreflex sensitivity. However, celiprolol 
has a significant vasodilatation action and therefore this effect would apply more to 
metoprolol group, and consequently the real effect of metoprolol would be 
underestimated. 
Repeatability of the measurements was acceptable but the standard deviation 
of the results recorded on three separate occasions was wide for some of the 
measurements. However, this may represent true variation of sympathetic and 
parasympathetic activity although we tried to repeat the recordings under identical 
conditions. Van de Borne et al (Van de Borne, Montano et al. 1997) confirmed that, 
even over an extended period, there is synchrony between changes in absolute 
measurements of R-R spontaneous fluctuations and directly recorded muscle 
sympathetic nerve activity and their respective spectral components. 
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Thus, some degree of the variation in repeat recordings may be due to real 
changes in underlying autonomic activity. A technical limitation of this technique in 
heart failure that we encountered was the difficulty in obtaining good recordings. 
This was mainly because of the HF of ectopic beats in some patients, which required 
linear interpolation. We discarded those recordings comparing more than 10% 
ectopic beats on a previous 24-hour Holter recording. 
5.4.8 Summary 
In conclusion, in this study we have demonstrated that the baroreflex gain of 
the heart rate - SBP relationship is impaired in heart failure compared with normal 
subjects and that after treatment with metoprolol, baroreflex gain improves and HF 
power (representing vagal tone) is enhanced. However, these changes were not seen 
with celiprolol. This may relate to the greater ease with which metoprolol can cross 
the blood brain barrier compared to celiprolol, exerting a direct central effect on 
autonomic and baroreceptor function in heart failure. 
An alternative explanation is that the vasodilator action and agonist activity of 
celiprolol offsets any advantage that accrues through P-adrenergic receptor 
antagonism. Thus, the ancillary properties of different (3-blockers may have 
important consequences for the treatment of heart failure. 
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5.5 P-Blockade in Heart Failure: A Comparison of Carvedilol with 
Metoprolol on HRV by 24 hour ECG Recordings (Time-
Domain & Spectral Analysis) 
/ 
In this study we were interested to compare metoprolol with carvedilol on 
clinical symptoms and autonomic function. As before in this larger clinical study, 
we used 24 hour Holter monitoring to assess HRV indices. As outlined earlier, 
carvedilol has been used in several large clinical trials for the treatment of heart 
failure. At the time of this study there had not been any direct head-to-head 
comparison of the two most commonly used p-blockers- metoprolol and carvedilol. 
5.5.1 Trial Design and Patient Demographics 
This was a randomized, double-blind, parallel group controlled trial. The 
inclusion and exclusion criteria for this study were identical to the previous study. 
After baseline measurements patients were randomized to receive treatment either 
with metoprolol or carvedilol. 
Dosing regimen (including dose titration and maintenance), measurements, 
and verification of compliance were similar to the previous study comparing 
metoprolol with celiprolol. There was a four week dose titration period increasing 
the dose of carvedilol from 3.125 to 25mg twice daily and metoprolol from 6.25 to 
50mg twice daily. Doses were increased at weekly intervals. Maintenance of doses 
was continued for a further 8 weeks giving a total of 12 weeks of treatment. At the 
end of 12 weeks, baseline measurements were repeated. 
5.5.2 Study Measurements 
Measurements included assessment of symptoms using the Minnesota Heart 
Failure Symptom Questionnaire, NYHA class, and routine clinical examination 
(pulse, heart rate, sitting and standing blood pressure, examination of jugular venous 
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pressure, position of the apex beat and presence or absence of a heart murmur or lung 
rales). A six-minute corridor walk test was carried out. Two baseline walk tests 
were carried out and the result averaged. Routine two-dimensional Doppler 
echocardiography was performed with measurement of left ventricular dimensions. 
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Pulsed-wave Doppler echocardiography was performed to assess mitral inflow 
velocities. Radionucleotide ventriculography (MUGA) was used to assess LV 
ejection fraction. 
HRV analysis: A 24-hour ambulatory ECG monitoring (Holter) was performed at 
baseline and at 12 weeks. Analysis was undertaken using the Marquette 
(Milwaukee, Wisconsin) MARS 8000 analyzer. Standard measurements of HRV by 
spectral and time domain analysis were undertaken (Anonymous 1996). 
5.5.3 Statistical Analysis 
Differences between the treatment groups were carried out by repeated 
measures analysis of variance for continuous variables (ANOVA) with Bartlett's test 
with homogeneity variances and Tukey-Kramer multiple comparison test if p < 0.05, 
Friedman's test for non-parametric data and Fisher exact test for differences between 
proportions. Differences between baseline and week 12 within groups were tested 
by paired t tests, and Wilcoxon matched pairs signed ranks test for non-parametric 
data. The results are expressed as mean 土 SEM. Differences were considered 
significant if p < 0.05. 
5.5.4 Results 
Subjects _ Fifty-one patients with a mean LV ejection fraction of 26 士l.go/o 
were recruited in the study, twenty-six receiving metoprolol and twenty-five 
receiving carvedilol. There were no significant differences in age, gender or other 
baseline characteristics (Table 17，page 100). The majority had idiopathic dilated 
cardiomyopathy (45%) with ischemic cardiomyopathy on the etiology in 22% and 
hypertensive heart disease in 33%. All but one patient were taking an angiotensin 
converting enzyme inhibitor or angiotensin II receptor antagonist. The average daily 
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dose of frusemide was similar in both groups. There were no significant differences 
between the two groups at baseline. 
Table 17 Baseline Clinical Characteristics of Study Patients 
Metoprolol Carvedilol group P value  
(n=26) (n=25)  
Age (years) 60.4 (2.3) 58.7(3.0) 0.65 
Range 35 to 80 33 to 86 
Sex 
Male 23 17 
Female 3 8 
Etiology 
IDC 10 13 
ICM 5 6 
HTHD 11 6 
NYHA functional class 
II 7 10 
III 19 14 
IV 0 1 
Mean NYHA class 2.7 (0.09) 2.6 (0.11) 0.53 
Symptom questionnaire score 13.1(1.8) 17.2(3.0) 0.23 
ETT (6 min walk, feet) 1164 (46) 1122 (51) 0.55 
Baseline Blood pressure (mm 
Hg) 
126(3)/75(3) 130(5)/78(3) 0.51/0.51 
Sitting 127(3)/78(3) 130(5)/83(3) 0.54/0.28 
Standing 
Heart rate (beats/min) 84.8 (2.5) 82.8 (2.7) 0.60 
LVEF (o/o) (Muga) 25.5 (1.8) 26.4(1.8) 0.72 
LVEDD (cm) 6.8(0.2) 6.7(0.2) 0.93 
FS (%) 13.8(1.0) 13.7(0.7) 0.88 
Treatment: 
Frusemide 24 24 
Frusemide mean dose (mg) 49 (7.0) 58 (8) 
ACEI/AIIRA 25 24 
Nitrates 16 16 
Values are mean 士 SEM. ACEI=angiotensin converting enzyme inhibitor; 
AIIRA=angiotensin II receptor antagonist; ETT = exercise tolerance test; FS = LV 
fractional shortening; HD = heart disease; HTHD = hypertensive heart disease; ICM 
=ischemic cardiomyopathy; IDC = idiopathic dilated cardiomyopathy; LVEF = LV 
ejection fraction (gated blood pool scan); LVedd = LV end diastolic dimension. 
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Withdrawals - In the carvedilol group five patients did not complete the 
study. Four patients were withdrawn due to worsening symptoms, in particular, 
weakness and dizziness. One patient was withdrawn because of the development of 
angioneurotic edema. In the metoprolol group, three patients were withdrawn, one 
because of increased breathlessness, who subsequently died. There were no 
differences in between carvedilol and metoprolol (p = 0.46, Fisher's exact test). 
Symptoms - The results of the symptom (quality of life) questionnaire score 
and assessment of NYHA functional class are shown in (Table 18, page 102). Both 
drugs were associated with a highly significant reduction in symptom questionnaire 
score and NYHA class. However, there were no significant differences between 
metoprolol and carvedilol. 
Blood Pressure and Heart Rate (Table 18, page 102) - At 12 weeks, 
carvedilol produced a highly significant (p < 0.001) reduction in sitting and standing 
systolic and diastolic blood pressures compared to baseline. Metoprolol had no 
significant effect on sitting systolic or diastolic blood pressure or standing SBP but 
had a mild effect on standing diastolic blood pressure. The differing effect on 
diastolic blood pressure between the two drugs was significant (p = 0.01). Both 
drugs had a highly significant effect on heart rate reducing the mean resting heart 
rate from 85 土 2.52 to 64 ± 2 bpm for metoprolol and 83 土 2.7 to 65 土 2.2 bpm for 
carvedilol (both p < 0.001). 
Exercise Capacity (Table 18，page 102) - Both drugs were associated with a 
significant improvement in exercise capacity as measured by the 6-min walk test. 
This effect appeared to be slightly greater with metoprolol than carvedilol, but the 
differences between the two drugs were not significant. 
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Table 18 Effects of Metoprolol or Carvedilol on Symptoms, Exercise Capacity, 




0 4 8 12 0 4 8 12 
Symptom 13.1 9 6.5 4.8* 17.2 13.1 11.3 8.1* 





I 0 1 1 1 0 1 0 1 
II 7 15 16 19 10 14 14 14 
III 19 9 7 3 14 8 6 5 
IV 0 0 0 0 1 0 0 0 
Mean 2.7 2.3 2.2 2.1* 2.6 2.3 2.3 2.2* 
(0.09) (0.11) (0.1) (0.09) (0.11) (0.11) (0.1) (0.12) 
Blood pressure 
(mm Hg) 
Sitting SBP 126 (3) 117(3) 121 (4) 117(4) 130(5) 122 (5) 121 (7) 116(6)* 
Sitting DBP 75 (3) 72(2) 70(2) " 72(2) 78(3) 70(4) 72(3) 68(3)* 
Standing SBP 127 (3) 120(3) 124(4) 122 (3) 130(5) 125(5) 123(6) 117(5)* 
Standing DBP 78(3) 74(2) 73 (3) 71 (3)t 83(3) 74(4) 74(3) 72(3)* 
Heart rate 84.8 65.7 64.1 64.1* 82.8 66.6 65.6 65.4* 
(beat/min) (2.5) (2.2) (3.1) (2.0) (2.7) (2.1) (2.2) (2.2) 
ETT 1164 1168 1162 1263t 1122 1098 1160 1194^ 
(6 min walk, (46) (48) (51) (52) (51) (49) (64) (63) 
feet) 
* p < 0.001 卞 p < 0.01 } p < 0.05, week 12 vs. baseline. 
DBP = diastolic blood pressure; ETT = exercise tolerance time; NYHA = New York 
Heart Association; SBP = systolic blood pressure. 
Left Ventricular Systolic Function (Table 19，page 103) - Both drugs 
produced a highly significant increase in left ventricular ejection fraction (metoprolol 
7 士 1.90/0 and carvedilol 8 士 l.P/o) but there was no significant difference between the 
drugs. Carvedilol, but not metoprolol reduced LV end-diastolic dimension 
significantly. 
Left Ventricular Diastolic Function (Table 19，page 103) - Neither drug 
produced a significant change of peak mitral E wave velocity. Both carvedilol and 
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metoprolol prolonged the deceleration time of the mitral E value towards normal, but 
this reached statistical significance only in the carvedilol group (p<0.001) in whom 
the deceleration time was normalized. There was also a reduction in the E/A ratio 
which was significant for both metoprolol and carvedilol. 
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Table 19 Effect of Metoprolol or Carvedilol Therapy on Systolic and Diastolic 
LV Function 
Metoprolol Carvedilol 
Baseline Week 1 2 B a s e l i n e Week 1 2 ~ 
LVEF % 25±1.8 31±2.5* 26±L8 35±2.6* 
LVFS 13.8±1.0 20±1.4* 13.6 20.9±1.4* 
LVedd (cm) 6.7±0.17 6.4±0.19 6.7土0.2 6.1 士0.3* 
Mitral E 0.77 土0.05 0.68土0.04 0.7±0.06 0.67土 0.06 
(cm/s) 
Mitral A 0.58±0.05 0.77±0.06| 0.6+0.07 0.7±0.09 
(cm/s) 
E/A ratio 1.6±0.2 1.1±0.2卞 1.5士0.2 1.0±0.2| 
Mitral DT 152±14 199±14 145 土 9.8 214±15* 
(ms)  
*p<0.001; t p<0 .01 ; t p<0.05 Week 12 vs. baseline 
LVedd = LV end-diastolic dimension; LVEF = LV ejection fraction; LVFS = LV 
fractional shortening; mitral A = peak velocity of mitral atrial wave; mitral DT = 
deceleration time of mitral E wave; mitral E = peak velocity of mitral early filling 
wave. 
Heart Rate Variability Indices (Table 20，page 104) _ Apart from the 
predictable changes on average, minimum and maximum heart rate and NN, there 
were no significant changes in any of the time domain or spectral heart rate 
variability indices between baseline and week 12 for either metoprolol or carvedilol. 
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Table 20 Effect of Metoprolol or Carvedilol on Spectral and Time Domain 
HRV Intervals 
Metoprolol Carvedilol 
Baseline Week 12 p value Baseline Week 12 p value 
/ 
Total Power 5.9土 0.20 5.7+ 0.26 0.42 5.9± 0.18 5.8±0.17 0.85 ln(ms2) 
LF Power 4.2土 0.27 4.2士 0.30 0.92 4.3士 0.28 4.4± 0.22 0.31 ln(ms2) 
HF Power 3.6+ 0.23 3.6士 0.24 0.89 3.4+ 0.20 3.5土 0.15 0.43 
In(ms^) 
NN(ms) 696.0土 21.5 830.09± 16.81 <0.001 729.3士 22.70 820.7± 20.03 <0.001 
SDNN (ms) 79.7土 3.93 86.2±5.50 0.20 82.9± 5.80 75.3土 4.50 0.16 
SDANN (ms) 70.7土 4.70 74.9土 5.62 0.48 73.7±5.31 63.13士 4.00 0.07 
SD (ms) 33.1 土 2.53 34.5土 2.03 0.63 36.5士4.48 36.8土 3.70 0.90 
rMSSD (ms) 20.9土 3.12 22.4士 1.51 0.65 19.5± 1.92 20.9士 1.47 0.24 
pNN50 (%) 5.3±2.6 4.1 士 0.71 0.67 3.0± 0.97 3.3土 0.89 0.63 
MINHR 59.1 士 2.27 47.5土 1.57 <0.001 53.1± 1.85 45.8土 2.08 <0.001 
(beats/min) 
Average HR 88.0±2.61 69.8±1.86 <0.001 83.1士 2.93 69.9土 2.00 <0.001 
MAXHR 133.2 士 5.17 106.7 土 3.69 <0.001 134.6±7.06 109.0士 4.75 <0.001 
(beats/min)  
HF = high frequency power (0.15 - 0.40 Hz); HR = heart rate; LF = low frequency 
power (0.04 -0 .15 Hz); NN = mean of all coupling intervals between normal beats; 
pNN50 = proportion of adjacent RRs more than 50 msec different; rMSSD = root-
mean square of difference of successive RRs; SD = mean of all 5-minute standard 
deviation of RRs; SDANN = standard deviation of 5 minute mean RR intervals; 




In this three-month study comparing metoprolol and carvedilol in patients 
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with CHF, we have demonstrated that both agents significantly improved symptoms 
(as judged by a Quality of Life Questionnaire and NYHA class), exercise capacity 
and left ventricular ejection fraction. 
Carvedilol lowered resting and sitting blood pressure more than metoprolol 
and also reversed the shortening of the deceleration time of the mitral E wave more 
than metoprolol. However, apart from these differences, there were no other 
apparent advantages of carvedilol over metoprolol. Both drugs have been shown 
previously to improve symptoms and left ventricular ejection fraction (Waagstein, 
Hjalmarson et al. 1975; Swedberg, Hjalmarson et al. 1979; Waagstein, Bristow et al. 
1993; Eichhom, Heesch et al. 1994; Bristow, Gilbert et al. 1996; Cleland, Bristow et 
al. 1996; Colucci, Packer et al. 1996; Packer, Bristow et al. 1996; Packer, Coined et 
al. 1996; Lechat, Packer et al. 1998; Sanderson, Chan et al. 1998). 
Our results differ slightly from those of Gilbert et al (Gilbert, Abraham et al. 
1996). In that study, the authors suggest that compared with metoprolol, carvedilol 
was associated with greater improvement in NYHA functional class, and there was a 
trend (all not significant) for carvedilol to produce a relatively greater improvement 
in LV ejection fraction, stroke volume and stroke work. However, unlike our study, 
it was not a randomized trial comparison of metoprolol against carvedilol but a meta-
analysis of two substudies from two different placebo controlled trials allowing for 
the possibility of considerable patient heterogeneity and bias. 
Effect on blood pressure - The greater effect on blood pressure by carvedilol 
is probably due to its a-adrenergic receptor antagonism properties. This effect on 
blood pressure was still apparent at 12 weeks, indicating that a receptor blockade is 
still operative after three-month therapy. In previous studies with a blockers in heart 
failure the benefits have not been sustained due to the development of tolerance. 
105 
Kukin et al (Kukin, Kalman et al. 1996) were unable to demonstrate any 
benefit of combined therapy with doxazosin and metoprolol compared to metoprolol 
alone after three months of continuous treatment. However, in hypertension Weber 
et al (Weber, Bohmeke et al. 1998) demonstrated that there was a chronic difference 
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between carvedilol and metoprolol, and their results suggest that carvedilol 
vasodilatory action is not subject to the development of tolerance. Our study would 
support this view. 
Heart rate variability - Neither carvedilol nor metoprolol significantly 
improved heart rate variability. In the previous study (see above), we demonstrated 
that metoprolol did improve HF power and baroreceptor function (Sanderson, Yeung 
et al. 1999). However, in that study the measurements were done over short 5- to 7-
minute recording periods during controlled respiration. In the UK-Heart Study 
(Nolan, Batin et al. 1998), heart failure patients with SDNN < 50 ms mortality had a 
significantly higher mortality. The majority of our patients had an SDNN of about 
80 ms. However, we were unable to demonstrate any improvement in this value 
following treatment with either metoprolol or carvedilol in this study. This is a 
surprising result given the obvious benefits seen with both drugs on LV ejection 
fraction and differs from the previous study comparing metoprolol with celiprolol 
where metoprolol appeared to significantly improve SDNN. Again this may reflect 
the limitations of 24-hour ECG recordings for assessing HRV. 
Limitations of the Study - This study had a relatively small number of 
patients and there is a possibility of a type II error. It was not powered to detect any 
differences in mortality and was designed to determine if there were any obvious or 
major differences in clinical efficacy especially in terms of symptoms, quality of life, 
and exercise capacity between the two drugs. To this extent, we used a wide range 
of well-validated techniques including the Minnesota Heart Failure Symptom 
Questionnaire and the 6-minute walk test. Several studies have now demonstrated a 
clear independent inverse relation between the 6-minute walk test and both mortality 
and morbidity (Yusuf and Tsuyuki 1996). 
We did not have a placebo group in the study. When planning this study, 
several larger scale studies had already confirmed the benefit of P-blockade in CHF 
106 
compared to placebo. Furthermore, in our previous study (Sanderson, Chan et al. 
1998) there were no significant changes in symptoms, exercise capacity on LVEF 
over the 12 week study period in the placebo group. There was a nonsignificant 




In this study, we have confirmed the beneficial effects of metoprolol and 
carvedilol in patients with CHF. We were unable to show any differences between 
carvedilol and metoprolol on symptoms, quality of life, and exercise capacity, left 
ventricular ejection fraction or heart rate variability. 
Carvedilol did lower both systolic and diastolic blood pressure significantly 
more than metoprolol and normalized the mitral E wave deceleration time. It is 
possible that these additional effects on blood pressure and diastolic function, which 
may be mediated by a receptor blockade, will translate into improved mortality and 
morbidity in the longer term, but in terms of improving symptoms, exercise capacity, 
LV ejection fraction or autonomic function, the additional actions of carvedilol do 
not appear to provide any additional benefit compared to metoprolol. 
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5.6 Comparison of Carvedilol and Metoprolol on Baroreceptor 
Gain in Heart Failure by Short Term Spectral Analysis 
In view of the negative results of the above study which utilized 24 hour 
Holter recordings we conducted another substudy using the more controlled short 
recordings with spectral analysis. 
5.6.1 Study Design 
This study had the same design as that above. Fourteen patients received 
metoprolol and ten carvedilol in the same doses and the same dose titration schedule. 
5.6.2 Study Patients 
Fifty-one patients with clinical diagnosis of congestive heart failure on 
standard therapy with diuretics, ACE inhibitors and digoxin with LVEF < 45% (by 
radionucleotide ventriculography or echocardiography) were recruited. Thirty-one 
normal subjects were also studied. 
5.6.3 Recording Technique and Protocol 
ECG recordings, finger blood pressure (Finapres) and respiration rate were 
taken in five to seven minute periods during spontaneous respiration and controlled 
breathing (15 breaths/min, 0.25 Hz) supine and standing. 
All these were applied as described in section 5.1.2, page 42. 
5.6.4 Signal Acquisition, Power Spectral Analysis and Cross Spectral Analysis 
Signal acquisition and power spectral analysis was performed using an 
autoregressive model. VLF (0.0033 - 0.04Hz), LF (0.04 - 0.15 Hz) and HF (0.15 -
0.4 Hz) components for both HR and SBP are presented in normalized units (nu) 
after subtraction of VLF. 
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All these were applied as described in section 5.1.3, page 42，section 5.1.4, 
page 43 and section 5.2.2, page 57 . 
5.6.5 Statistical Analysis 
All these were applied as described in section 5.4.5, page 84. 
5.6.6 Results 
1. In the carvedilol group five patients did not complete the study. Four patients 
were withdrawn due to worsening symptoms, in particular, weakness and 
dizziness. One patient was withdrawn because of the development of 
angioneurotic edema. In the metoprolol group, three patients were 
withdrawn, one because of increased breathlessness, who subsequently died. 
We discarded those recordings comparing more than 10% ectopic beats on a 
previous 24 hour Holter recording. In this study, satisfactory spectral data on 
each occasion were obtained in twenty four patients with fourteen receiving 
metoprolol and ten receiving carvedilol. Thirty one normal subjects were 
also studied. 
2. Baroreceptor gain was significantly depressed in heart failure patients 
compared to a normal control group (heart failure = 6.54 士 1.02; normal = 
11.73 士 1.32 msec/mniHg; p < 0.0001). 
3. After treatment with metoprolol, baroreceptor gain improved from 6.13 士 
0.96 at baseline to 10.13 ± 1.18 msec/mmHg at 12 weeks (p = 0.029). In 
contrast baroreceptor gain after treatment with carvedilol (7.18 士 2.21 to 9.34 
士 2.16 msec/mmHg) was not significant. Heart rate reductions were similar 
in both groups (Table 21, page 110，Figure 16, page 110). 
4. HF power (nu) tended to increase with both metoprolol and carvedilol with 
significant difference at 8 week, but the differences were not significant at 12 
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weeks compared to baseline (Table 22，page 111) & (Table 23, page 111). 
As expected both drugs had a highly significant effect on R-R interval. 
Table 21 a Angle Measured with Paced Respiration (15 breaths/mins)-Supine 
WeekO Week 4 Week 8 Week 12 
Metoprolol 6.1±0.9 6.9±1.06 10.3+1.6* 10.1 土 1.1* 
Carvedilol 7.2±2.2 8.6±2.0 9.4 士 3.4 9.3±2.1 
* p < 0.05 (week 4, 8 or 12 versus week 0) 
aHF (Supine 15) 
8-] 普 Metoprolol 
-^Carvedilol 
^ 6 -O) T 
X u- E 
^ TJ 4- / t p = 0 . 0 2 9 
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Figure 16 Change in HF a angle (aHF) from baseline at weeks 4，8 and 12， 
measured in the supine position with paced respiration (15 breaths/min) in the 
two treatment groups. 
Values are mean 士 SEM，p: compared with baseline 
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Table 22 Heart Rate Variability - Power Spectral (Controlled Respiration 一 
Supine) 
Mean LF HF LF/HF 
(ms) (n^ (nu}  
Metoprolol therapy 
WeekO 807士40.7 20.4+5.6 57.7土 4.5 0.5 士 0.2 
Week 4 997±44.6** 25.8+6.8 60.7±5.2 0.6+0.2 
Week 8 1049士41.6** 16.3土2.5 70.0土4.7* 0.2±0.05 
Week 12 1053+38.1** 18.3士5.9 72.5士 6.1 0.5±0.3 
Carvedilol therapy 
WeekO 835+47.7 19.1 土7.2 54.0土 8.0 0.5±0.2 
Week 4 1049+65.0** 20.6土6.0 67.5±7.1 0.4±0.1 
Week 8 1024+64.2** 12.7±3.7 74.6土5.0* 0.2土0.08 
Week 12 1018±64.4** 41.8±9.1* 49.7 士 8.1 2.4±1.2 
*p<0.05 ** P < 0.01 (week 4，8 or 12 versus week 0)，LF = low frequency power; 
HF = high frequency power; nu = normalized units 
Table 23 Systolic Blood Pressure Variability during Controlled Respiration 一 
Supine 
Mean LF (nu) HF (nu) LF/HF 
Metoprolol therapy 
WeekO 127 土4.7 22.3±8.0 48.4+8.8 1.0士 0.4 
Week 4 112±10.1 16.1±4.3 71.7±6.4* 0.3 土 0.1 
Week 8 115+6.2* 24.6+7.0 72.4士 6.5 0.8±0.5 
Week 12 123±5.6 27.9+7.1 65.3士 6.5 0.9士0.4 
Carvedilol therapy 
WeekO 122+6.4 27.0+10.1 53.1+11.2 2.1±1.5 
Week 4 114±5.4 19.3 土6.3 73.4士 8.0 0.4±0.2 
Weeks 117±8.8 21.8+7.1 71.5 士 8.0* 0.5+0.2 
Week 12 118+4.2 18.7 士5.4 73.8+6.0 0.3±0.1 
*p<0.05 (week 4, 8 or 12 versus week 0), LF = low frequency power; HF = high 
frequency power; nu = normalized units 
111 
5.6.7 Discussion 
In this study we were able to confirm that both metoprolol and carvedilol 
increased HF power suggesting an effect on increasing vagal activity. Again this is 
/ 
in contrast to the previous study using the Holter 24 hour recordings. Once more this 
probably reflects the importance of controlling respiration in for the spectral analysis 
of HRV. 
However, although it appeared both drugs improved baroreceptor function 
this was only significant for metoprolol. This is in slight contrast to the study by 
Mortara et al (Mortara, La Rovere et al. 2000) who found that carvedilol did increase 
baroreflex sensitivity (measured by the phenylephrine method) after 6 months 
therapy. It is possible that a repeat measurement in our study at 6 months may have 
produced a significant difference. However, the study by Mortara et al was not a 
randomized study and the controls were historical controls. It is also possible that 
the lack of statistical significance for the carvedilol group is due to the smaller 
number of subjects who completed the study with satisfactory recordings for RR and 
SBP. 
5.6.8 Summary 
In this study we have demonstrated that the baroreflex gain of the heart rate -
SBP relationship is impaired in heart failure compared to controls and that after 
treatment with metoprolol baroreflex gain improved. 
However, although there was a trend for improvement with carvedilol this not 
reaches statistical significance. Thus these results suggest that metoprolol has a 
superior effect on restoring baroreceptor gain towards normal which may be due to a 
direct central effect of metoprolol which is greater than that of carvedilol despite 
both being lipophilic drugs. 
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6 GENERAL DISCUSSION, LIMITATIONS & CONCLUSIONS 
6.1 Discussion 
/ 
These studies have demonstrated the usefulness of HRV techniques as 
markers of autonomic dysfunction in heart failure and for assessing the impact of 
treatment with P-blockers. In addition we have shown that slow breathing is a 
simple and effective method for improving baroreceptor function. We have also 
confirmed that HRV is severely reduced in heart failure and there is a paradoxical 
reduction in low-frequency (LF) power. The possible reasons for this have been 
discussed in the previous sections. However, there were some inconsistencies in the 
results particularly between those using 24 hour Holter ECG recordings and the 
short-term recording spectral HRV analyses (the Bemardi method). There are 
possible reasons for this. 
Time-Domain versus Frequency-Domain fspectral) analyses 
Based on mathematical theory, the variance of the interval between heart 
beats which is equivalent to the time-domain measurement SDNN and total power in 
the frequency domain are identical. However, total power is often used to represent 
the combination of the HF and LF power which reflects only a portion of the total 
spectrum. Kleiger et al (Kleiger, Bigger et al. 1991) found that in normals subjects 
pNN50 and rMSSD had very strong (>0.85) positive correlations with HF power 
which is in the range of frequencies associated with breathing (0.15 to 0.4 Hz). 
Since the majority of short-term variance in HR is mediated by respiratory sinus 
arrhythmia this close relationship is not surprising. Bigger et al (Bigger, Fleiss et al. 
1992) found in their study of post myocardial infarction patients that for every band 
of the 24 hour HR spectrum there is at least one time-domain correlate (Table 24, 
pagell4). As in normals parameters known from previous work to reflect 
parasympathetic activity (i.e. pNN50 and rMSSD) correlated well with HF power. 
SDNN index had very strong correlation with VLF, LF, and HF suggesting it is 
influence by both vagal and sympathetic activity. In fact SDNN is a surrogate for 
total power. However, in our studies we did not always find such a good correlation. 
For example, in the celiprolol versus metoprolol comparison using 24 hour 
113 
recordings SDNN and SDANN increased significantly but the increase in total power 
was not significant although there was a trend towards an increase. Interestingly in a 
recent study by Tygesen et al (Tygesen, Rundquist et al. 2001) there was a strong 
correlation between LF/HF during orthostatic stress and cardiac sympathetic activity 
/ 
measured as myocardial norepinephrine spillover during supine rest. There was no 
correlation with LF, HF or LF/HF in the supine position or with any time-domain 
measurement. The authors used short-term recordings with controlled respiration for 
measurement of the frequency-domain parameters. Thus although there may be a 
good correlation in normals, in patients with heart failure it is not so clear. The 
method of recording may be more relevant in heart failure subjects. 
Table 24 Correlations between Time and Frequency-Domain Measures of HRV 
in Patients after Myocardial Infarction 
Time Frequency Domain  
Domain TP UI^ W LF HF 
SDNN 0.96 0.95 0.78 0.72 0.67 
SDANN 0.94 0.96 0.68 0.61 0.57 
SDNN index 0.79 0.71 0.90 0.89 0.82 
pNN50 0.56 0.50 0.59 0.64 0.89 
rMSSD 0.58 OM 0.92 
Abbreviations: SDNN: standard deviation of all NN intervals over a 24-hr period; 
SDANN: standard deviation of the average NN intervals for all 5-minute segments of 
a 24-hour recording; SDNN index: mean of the standard deviations of all NN 
intervals for all 5-minute segments of a 24-hour recording; pNN50: proportion of 
adjacent NN intervals >50ms different over the entire 24-hour recording; rMSSD: 
root mean square of differences between adjacent NN intervals in a 24-hour 
recording; TP: total power of the heart power spectrum (0 to 0.40 Hz); ULF: ultra 
low frequency power (0 to 0.0033 Hz); VLF: very low frequency power (0.0033 to 
0.04 Hz); LF: low frequency power (0.04 to 0.15 Hz); HF: high frequency power 
(0.15 to 0.40 Hz). Adapted from (Bigger, Fleiss et al. 1992) 
T.ong-term versus short-term recordings 
Most of the data derived from spectral HRV analysis in the literature has 
come from short-tem recordings in the laboratory under controlled conditions such 
as under rest, standing or supine, and with controlled respiration. Often the software 
is custom made (as in our studies from the laboratory of Dr Bemardi, Pavia, Italy) 
and it is possible to vary some technical aspects such as windowing, detrending, or 
resampling of the time series or choice of the model order utilized to estimate the 
spectral density. 
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In contrast, Holter based analyses use commercial software which have 
limited flexibility and generally use the FFT (Fast Fourier transform) method rather 
than the autoregressive modeling technique which allows easier post processing of 
/ 
the spectrum with an automatic computation of the power and center frequency of 
each detected component. Since the center frequency of LF and HF can vary 
particularly with relation to the respiratory rate and additional factors that may affect 
the sinus node. This may be especially important in heart failure patients where the 
LF power is weak and the respiratory rate may be higher than normal. Furthermore, 
the commercial software does not allow the ability to remove artifacts without 
directly affecting the time series duration. Of course ambulatory recordings will 
include variable amounts of physical activity, sleep and environmental factors. In 
many studies which use Holter techniques the spectral analyses are discarded in 
favour of the time-domain measurements. With short-term recordings it is also 
possible to record the arterial blood pressure non-invasively and the respiratory rate 
which allows by cross-spectral analysis, the coherence and phase between 2 variables 
signals and hence assess tonic baroreceptor function. 
Our studies would support the view that short-term recordings during 
controlled conditions and combined with recordings of other variables such as SBP 
or respiration is the most effective and reliable approach to non-invasively 
autonomic modulation of heart rate and cardiovascular control. 
Ectopic beats 
Most frequently, the QRS complexes of atrial and ventricular ectopic beats 
are not interpolated within the NN sequences subjected to time domain measurement 
of HRV, but simply removed including their coupling intervals and compensatory 
pauses. The recent study found that the so-called heart rate turbulence indicates that 
not only the compensatory pause but a number of subsequent NN intervals are 
influenced by an ectopic beat. 
Hence, further methodological studies are needed to establish the correct way 
of coping with ectopic beats within the NN interval sequence to obtain truly 
representative HRV values. It seems likely that the current practice of ignoring 
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ectopic beats after their coupling intervals and compensatory pauses are removed 
from the NN data stream may need to be revised (Wojciech, Pierre et al. 2001). 
The importance of standardization was further emphasized in the study by 
Woo et al. (Woo, Stevenson et al. 1996), who compared four methods — RR interval 
histograms, standard deviation, Poincare plots and spectral analysis. For those 
assessed over a 24 hour period, there were similar but not identical results, with 
agreement ranging from 69 to 96%. Spectral analysis using short periods of 
recordings showed considerable variation, which is likely to be due to a difference in 
activity, posture and breathing rates. If short recordings are used, comparison can 
only be made when the recordings are performed under strictly standardized and 
controlled conditions. 
Comparison of studies in this area is difficult because as stated most of the 
short-term studies which are the most useful use custom-made software with great 
differences in terms of detecting the QRS complex, number of cycles analyzed, 
windowing, detrending and resampling of time series. Also there are differences 
sometimes between the methods using FFT and autoregressive algorithms which in 
certain conditions can provide slightly different results. 
A further problem with spectral analysis in heart failure is reproducibility, 
especially if there is frequent ectopic activity. Interpolation of recordings has to be 
done carefully and by an experienced operator. Few studies have addressed the 
question of reproducibility in heart failure. In our study we found on repeated 
measurements that the mean difference in absolute units for HF was 3.2 土 1.5% 
supine and 3.75 土 2o/o standing. Reproducibility for spectral analysis of SBP was 
poor, especially for the LF band. 
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6.2 Conclusions 
Autonomic dysfunction is an important aspect of heart failure and this is 
reflected in reduced heart rate variability. Using spectral analysis, some indication of 
these abnormalities can be obtained. 
The precise origin of the LF component and the reason why it is depressed or 
absent in heart failure is unclear at present but it likely reflects a central effect that 
affects sympathetic and vagal outflow and baroreceptor fiinction. Thus, the rather 
simplistic approach of assuming that the LF and HF components reflect sympathetic 
and parasympathetic activity is likely to be invalid. It is more probable that these 
measurements reflect overall autonomic control of the vasculature and in particular 
the central impairment of baroreceptor function. 
In this context, baroreceptor function, which is more representative of overall 
cardiovascular control, is likely to be .more relevant and will impact on prognosis 
through the development of cardiac arrhythmias. Although there are a number of 
techniques now to study HRV they have important limitations and we still need more 
reliable non-invasive techniques for the assessment of autonomic and baroreceptor 
function in heart failure. 
Respiratory rate and changes in posture have a significant effect on 
measurements derived from spectral analysis of heart rate and blood pressure 
variability. Studies that use power spectral analysis as a measure of sympatho-vagal 
balance should control for these variables. 
In patients with CHF, slow breathing, in addition to improving oxygen 
saturation and exercise tolerance as previously shown, may be beneficial by 
increasing baroreflex sensitivity. 
Celiprolol and metoprolol were well tolerated but the ancillary vasodilator 
properties of celiprolol do not appear to provide any obvious additional clinical 
benefit compared to metoprolol in the long-term treatment of heart failure. In 
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addition Metoprolol but not celiprolol therapy restores baroreceptor gain towards 
normal and increases vagal tone in CHF. 
Both metoprolol and carvedilol were equally effective in improving 
symptoms, quality of life, exercise capacity and LV ejection fraction although 
carvedilol has a greater effect in lowering blood pressure than metoprolol. However, 
metoprolol appeared to restore the depressed baroreceptor function found in heart 
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